Tumors or cancer of the LUNG.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A malignant epithelial tumor with a glandular organization.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A cell line derived from cultured tumor cells.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Pathological processes involving any part of the LUNG.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Tumors or cancer of the LIVER.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Cell surface proteins that bind bombesin or closely related peptides with high affinity and trigger intracellular changes influencing the behavior of cells. Gastrin- releasing peptide (GRP); GRP 18-27 (neuromedin C), and neuromedin B are endogenous ligands of bombesin receptors in mammals.
DNA present in neoplastic tissue.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
Antibodies produced by a single clone of cells.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Transplantation between animals of different species.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
The excision of lung tissue including partial or total lung lobectomy.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
An organoplatinum compound that possesses antineoplastic activity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
The transference of either one or both of the lungs from one human or animal to another.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Tumors or cancer of the BRONCHI.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Established cell cultures that have the potential to propagate indefinitely.
Elements of limited time intervals, contributing to particular results or situations.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease.
An autoimmune disease characterized by weakness and fatigability of proximal muscles, particularly of the pelvic girdle, lower extremities, trunk, and shoulder girdle. There is relative sparing of extraocular and bulbar muscles. CARCINOMA, SMALL CELL of the lung is a frequently associated condition, although other malignancies and autoimmune diseases may be associated. Muscular weakness results from impaired impulse transmission at the NEUROMUSCULAR JUNCTION. Presynaptic calcium channel dysfunction leads to a reduced amount of acetylcholine being released in response to stimulation of the nerve. (From Adams et al., Principles of Neurology, 6th ed, pp 1471)
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Tumors or cancer of the human BREAST.
RNA present in neoplastic tissue.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
A group of acidic proteins that are major components of SECRETORY GRANULES in the endocrine and neuroendocrine cells. They play important roles in the aggregation, packaging, sorting, and processing of secretory protein prior to secretion. They are cleaved to release biologically active peptides. There are various types of granins, usually classified by their sources.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
A type I keratin found associated with KERATIN-7 in ductal epithelia and gastrointestinal epithelia.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Tumors or cancer of the THYROID GLAND.
A sarcoma characterized by the presence of small cells, cells measuring 9-14 micrometers with a faint or indistinct rim of cytoplasm and an oval-to-elongated nucleus with relatively dense chromatin. (From Segen, Dictionary of Modern Medicine, 1992)
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
Tumors or cancer of the ESOPHAGUS.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Tumors or cancer of the NASOPHARYNX.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
A type of chromogranin which was first isolated from CHROMAFFIN CELLS of the ADRENAL MEDULLA but is also found in other tissues and in many species including human, bovine, rat, mouse, and others. It is an acidic protein with 431 to 445 amino acid residues. It contains fragments that inhibit vasoconstriction or release of hormones and neurotransmitter, while other fragments exert antimicrobial actions.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Agents that inhibit PROTEIN KINASES.
Cerebellar degeneration associated with a remote neoplasm. Clinical manifestations include progressive limb and GAIT ATAXIA; DYSARTHRIA; and NYSTAGMUS, PATHOLOGIC. The histologic type of the associated neoplasm is usually carcinoma or lymphoma. Pathologically the cerebellar cortex and subcortical nuclei demonstrate diffuse degenerative changes. Anti-Purkinje cell antibodies (anti-Yo) are found in the serum of approximately 50% of affected individuals. (Adams et al., Principles of Neurology, 6th ed, p686)
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the URINARY BLADDER.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
A condition of HYPONATREMIA and renal salt loss attributed to overexpansion of BODY FLUIDS resulting from sustained release of ANTIDIURETIC HORMONES which stimulates renal resorption of water. It is characterized by normal KIDNEY function, high urine OSMOLALITY, low serum osmolality, and neurological dysfunction. Etiologies include ADH-producing neoplasms, injuries or diseases involving the HYPOTHALAMUS, the PITUITARY GLAND, and the LUNG. This syndrome can also be drug-induced.
A system of NEURONS that has the specialized function to produce and secrete HORMONES, and that constitutes, in whole or in part, an ENDOCRINE SYSTEM or organ.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Inhaling and exhaling the smoke of burning TOBACCO.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
A MARVEL domain-containing protein found in the presynaptic vesicles of NEURONS and NEUROENDOCRINE CELLS. It is commonly used as an immunocytochemical marker for neuroendocrine differentiation.
Specialized NEURONS that produce hormones, such as NEUROPEPTIDES or BIOGENIC AMINES. They generally are in the NERVOUS SYSTEM, such as HYPOTHALAMUS, but can be found in other organs or systems. These neurons contain dense neurosecretory granules and PROPROTEIN CONVERTASES allowing the rapidly release of NEUROHORMONES into the blood circulation upon stimulation.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
The action of a drug in promoting or enhancing the effectiveness of another drug.
Endoscopic examination, therapy or surgery of the bronchi.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8.
A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Biochemical identification of mutational changes in a nucleotide sequence.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Tumors or cancer of the SKIN.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Treatment that combines chemotherapy with radiotherapy.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Degenerative or inflammatory conditions affecting the central or peripheral nervous system that develop in association with a systemic neoplasm without direct invasion by tumor. They may be associated with circulating antibodies that react with the affected neural tissue. (Intern Med 1996 Dec;35(12):925-9)
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
A diffuse or multifocal peripheral neuropathy related to the remote effects of a neoplasm, most often carcinoma or lymphoma. Pathologically, there are inflammatory changes in peripheral nerves. The most common clinical presentation is a symmetric distal mixed sensorimotor polyneuropathy. (Adams et al., Principles of Neurology, 6th ed, p1334)
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Tumors or cancer of the COLON.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Cells with the capacity to take up and decarboxylate the amine precursors DIHYDROXYPHENYLALANINE or 5-HYDROXYTRYPTOPHAN. This is a property of endocrine cells of neural and non-neural origin. APUDOMA is a general term collectively applied to tumors associated with APUD cells.
The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.
A mixture of six synthetic oligopeptides, each containing MELPHALAN. It is used as a broad-spectrum antineoplastic due to its alkylating and antimetabolic actions but, is toxic to bone marrow, gastrointestinal system and vasculature.
Tumors or cancer of the STOMACH.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Tumors or cancer of the MOUTH.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Actual loss of portion of a chromosome.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
A paraneoplastic syndrome marked by degeneration of neurons in the LIMBIC SYSTEM. Clinical features include HALLUCINATIONS, loss of EPISODIC MEMORY; ANOSMIA; AGEUSIA; TEMPORAL LOBE EPILEPSY; DEMENTIA; and affective disturbance (depression). Circulating anti-neuronal antibodies (e.g., anti-Hu; anti-Yo; anti-Ri; and anti-Ma2) and small cell lung carcinomas or testicular carcinoma are frequently associated with this syndrome.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)

Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. (1/7523)

The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.  (+info)

Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. (2/7523)

OBJECTIVE: To determine the sensitivity, specificity, and accuracy of positron emission tomography with 2-fluorine-18-fluorodeoxyglucose (PET-FDG) in the preoperative staging (N and M staging) of patients with lung cancer. The authors wanted to compare the efficacy of PET scanning with currently used computed tomography (CT) scanning. MATERIALS AND METHODS: Results of whole-body PET-FDG imaging and CT scans were compared with histologic findings for the presence or absence of lymph node disease or metastatic sites. Sampling of mediastinal lymph nodes was performed using mediastinoscopy or thoracotomy. RESULTS: PET-FDG imaging was significantly more sensitive, specific, and accurate for detecting N disease than CT. PET changed N staging in 35% and M staging in 11% of patients. CT scans helped in accurate anatomic localization of 6/57 PET lymph node abnormalities. CONCLUSION: PET-FDG is a reliable method for preoperative staging of patients with lung cancer and would help to optimize management of these patients. Accurate lymph node staging of lung cancer may be ideally performed by simultaneous review of PET and CT scans.  (+info)

Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. (3/7523)

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. (4/7523)

Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 years shows that in women specifically, lung cancer incidence is on the rise. It is estimated that 10-20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an effort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using six 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined. The regions of LOH identified included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453. These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.  (+info)

Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. (5/7523)

BACKGROUND: Conventional cytologic analysis of sputum is an insensitive test for the diagnosis of non-small-cell lung cancer (NSCLC). We have recently demonstrated that polymerase chain reaction (PCR)-based molecular methods are more sensitive than cytologic analysis in diagnosing bladder cancer. In this study, we examined whether molecular assays could identify cancer cells in bronchoalveolar lavage (BAL) fluid. METHODS: Tumor-specific oncogene mutations, CpG-island methylation status, and microsatellite alterations in the DNA of cells in BAL fluid from 50 consecutive patients with resectable (stages I through IIIa) NSCLC were assessed by use of four PCR-based techniques. RESULTS: Of 50 tumors, 28 contained a p53 mutation, and the identical mutation was detected with a plaque hybridization assay in the BAL fluid of 39% (11 of 28) of the corresponding patients. Eight of 19 adenocarcinomas contained a K-ras mutation, and the identical mutation was detected with a mutation ligation assay in the BAL fluid of 50% (four of eight) of the corresponding patients. The p16 gene was methylated in 19 of 50 tumors, and methylated p16 alleles were detected in the BAL fluid of 63% (12 of 19) of the corresponding patients. Microsatellite instability in at least one marker was detected with a panel of 15 markers frequently altered in NSCLC in 23 of 50 tumors; the identical alteration was detected in the BAL fluid of 14% (three of 22) of the corresponding patients. When all four techniques were used, mutations or microsatellite instability was detected in the paired BAL fluid of 23 (53%) of the 43 patients with tumors carrying a genetic alteration. CONCLUSION: Although still limited by sensitivity, molecular diagnostic strategies can detect the presence of neoplastic cells in the proximal airway of patients with surgically resectable NSCLC.  (+info)

Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu. (6/7523)

In a trimodality treatment approach for stage III non-small cell lung cancer the prognostic impact of pretherapeutic p185neu assessment was evaluated. Fifty-four patients were admitted to chemotherapy followed by twice-daily radiation with concomittant low-dose chemotherapy and subsequent surgery. Immunohistochemical assessment of p185neu expression was performed in paraffin-embedded mediastinal lymph node metastases, by mediastinoscopy biopsy prior to therapy. Paraffin-embedded biopsies of mediastinal lymph node metastases were available in 33 cases. Seven out of eight patients with positive p185neu staining developed distant metastases, in contrast to seven out of 25 negative cases. Expression of p185neu in mediastinal lymph node metastases was a significant predictor for progression-free survival (p=0.047) and resulted mainly from significant differences in metastases-free survival (p185neu-positive versus p185neu-negative: median, 11 versus 19 months; 2- and 3-yr rates, 13% and 0% versus 40% and 32%; p=0.04). On the basis of these preliminary results it was concluded that further evaluation of p185neu expression in trials on neoadjuvant and adjuvant therapy is warranted. When the prognostic impact of p185neu in such trials with larger patient numbers is confirmed, this may contribute to the identification of stratification variables for future treatment approaches of non-small cell lung cancer.  (+info)

Combined modality therapy of lung cancer. (7/7523)

Combined modality therapy for lung cancer was first demonstrated to be successful in limited-stage small cell lung cancer. Concurrent administration of chemotherapy with chest and elective brain irradiation appears to produce the best results, with cisplatin/etoposide as the core chemotherapy. Using such programs, 2-year survival in the 40% range and 5-year survivals in excess of 20% may be expected, based on the results of multiple studies. Attempts to improve on these results through the use of altered schemes of chest irradiation or the delivery of high-dose consolidation chemotherapy are ongoing but to date have not been shown to affect survival significantly. We remain at a plateau in the effectiveness of combined modality therapy for small cell lung cancer, with little evidence that it impacts survival at all in extensive-stage disease. The incorporation of new agents in combination chemotherapy regimens, more "specific" immunotherapy directed at tumor-associated antigens, and the potential adjunctive use of broad-spectrum neuropeptide antagonists offer promise for the future. In non-small cell lung cancer, the sequential use of platinum-based chemotherapy and chest irradiation appears superior in survival to standard, daily fractionated radiation therapy used alone, with long-term survival increased from 5-10% to 15-20%. Concurrent administration of chemotherapy with cisplatin/etoposide and chest irradiation produces 2-year survival in the range of 30%, about twice that would be expected for radiation therapy alone, but has not been compared to it in the setting of a randomized trial. Low-dose cisplatin on a daily basis has been combined as a "sensitizer" with chest irradiation, producing initial results that appeared encouraging. However, these have not been reproduced in subsequent, randomized trials. Another approach to combined modalities has been to give chemotherapy or chemotherapy/radiation therapy as induction, followed by surgical resection, with or without subsequent additional treatment. Most patients (80-85%) can be resected, with encouraging survival at 2 and 3 years in the Southwest Oncology Group experience (37 and 26%, respectively). However, toxicity is greater, and such an approach is associated with an overall mortality risk in the range of 10%. A current intergroup study attempts to define the role of surgery in this setting. The major recent development that is likely to influence the future of combined modality therapy for this disease is the advent of multiple new chemotherapeutic agents, such as the taxanes, gemcitabine, vinorelbine, and the topoisomerase-I inhibitors, which have activity in stage IV disease. The immediate challenge is how to combine these agents with platinum analogues, radiation, and surgery. Aiding this process may be the use of molecular biological "markers" that may predict the chance of success or failure with a given systemic agent. The next decade is likely to see substantial improvements in the outcome of treatment for patients with stages I-III non-small cell lung cancer, based on the systemic exploration of combined modalities.  (+info)

The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. (8/7523)

AIMS: To investigate the expression of beta-catenin in non-small-cell lung cancer (NSCLC) and its clinical significance. METHODS: 101 patients were surgically treated for NSCLC by lobectomy or pneumectomy with systematic lymph node dissection. Follow up was available in all patients, ranging from 24 to 110 months. Immunostaining of tissue sections from primary tumours and (when present) their lymph node metastases was performed and evaluated using a monoclonal antibody against beta-catenin. Correlations were investigated between beta-catenin immunostaining in primary tumours and E-cadherin immunostaining (data available from a previous study), lymph node stage, and survival. RESULTS: There were significant correlations between scores for beta-catenin immunostaining and E-cadherin immunostaining in primary tumours (p = 0.007), and between the beta-catenin immunostaining score in primary tumours and in their lymph node metastases (p = 0.006). An inverse correlation was found between the beta-catenin immunostaining score in primary tumours and lymph node stage N0, N1, or N2 (p = 0.03). According to the Kaplan-Meier survival estimate, the level of beta-catenin expression in primary tumours was a statistically significant prognostic factor (p = 0.01). CONCLUSIONS: Reduced beta-catenin expression in surgically treated NSCLC is clearly associated with lymph node metastasis and an infavourable prognosis. The existence of a functional relation between E-cadherin and beta-catenin is supported by the results of this clinicopathological study.  (+info)

There are several types of lung neoplasms, including:

1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.

Lung diseases can also be classified based on their cause, such as:

1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.

Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.

Adenocarcinoma is the most common subtype of NSCLC and is characterized by malignant cells that have glandular or secretory properties. Squamous cell carcinoma is less common and is characterized by malignant cells that resemble squamous epithelium. Large cell carcinoma is a rare subtype and is characterized by large, poorly differentiated cells.

The main risk factor for developing NSCLC is tobacco smoking, which is responsible for approximately 80-90% of all cases. Other risk factors include exposure to secondhand smoke, radon gas, asbestos, and certain chemicals in the workplace or environment.

Symptoms of NSCLC can include coughing, chest pain, shortness of breath, and fatigue. The diagnosis is typically made through a combination of imaging studies such as CT scans, PET scans, and biopsy. Treatment options for NSCLC can include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for NSCLC depends on several factors, including the stage of the cancer, the patient's overall health, and the effectiveness of treatment.

Overall, NSCLC is a common and aggressive form of lung cancer that can be treated with a variety of therapies. Early detection and treatment are critical for improving outcomes in patients with this diagnosis.

Epidemiology:

* Incidence: Small cell carcinoma (SCC) accounts for approximately 10%-15% of all skin cancers, but it is more common in certain populations such as fair-skinned individuals and those with a history of sun exposure.
* Prevalence: The prevalence of SCC is difficult to determine due to its rarity, but it is believed to be more common in certain geographic regions such as Australia and New Zealand.

Clinical features:

* Appearance: Small cell carcinoma usually appears as a firm, shiny nodule or plaque on sun-exposed areas of the skin, such as the face, ears, lips, and hands. It can also occur in other parts of the body, including the mucous membranes.
* Color: The color of SCC can range from pink to red to purple, and it may be covered with a crust or scab.
* Dimensions: SCC usually measures between 1-5 cm in diameter, but it can be larger in some cases.
* Surface: The surface of SCC may be smooth or rough, and it may have a "pearly" appearance due to the presence of small, white, and shiny nodules called "heidlebergs."

Differential diagnosis:

* Other types of skin cancer, such as basal cell carcinoma and squamous cell carcinoma.
* Other diseases that can cause similar symptoms and appearance, such as psoriasis, eczema, and actinic keratosis.

Treatment:

* Surgical excision: Small cell carcinoma is usually treated with surgical excision, which involves removing the tumor and some surrounding tissue.
* Radiation therapy: In some cases, radiation therapy may be used after surgical excision to ensure that all cancer cells are eliminated.
* Topical treatments: For more superficial SCC, topical treatments such as imiquimod cream or podofilox solution may be effective.

Prognosis:

* The prognosis for small cell carcinoma is generally good if it is detected and treated early.
* However, if left untreated, SCC can invade surrounding tissues and organs, leading to serious complications and potentially fatal outcomes.

Complications:

* Invasion of surrounding tissues and organs.
* Spread of cancer cells to other parts of the body (metastasis).
* Scarring and disfigurement.
* Infection and inflammation.

SCLC typically starts in the bronchi of the lungs and can spread quickly to other parts of the body, such as the brain, liver, and bones. It is often found in later stages and is associated with a poorer prognosis than non-small cell lung cancer (NSCLC).

There are two main types of SCLC:

1. Limited-stage SCLC: This type of SCLC is limited to one lung and has not spread to other parts of the body.
2. Extensive-stage SCLC: This type of SCLC has spread beyond one lung and may have spread to other parts of the body.

Symptoms of SCLC include:

* Coughing
* Chest pain
* Shortness of breath
* Weight loss
* Fatigue

Diagnosis of SCLC is typically made through a combination of imaging tests, such as chest X-rays, CT scans, and PET scans, and a biopsy to confirm the presence of cancer cells. Treatment options for SCLC include:

1. Chemotherapy: This is the primary treatment for SCLC and may be used alone or in combination with radiation therapy.
2. Radiation therapy: This may be used alone or in combination with chemotherapy to treat SCLC.
3. Surgery: In some cases, surgery may be possible to remove the tumor and affected tissue.
4. Clinical trials: These may be available for patients with SCLC to access new and innovative treatments.

Overall, SCLC is a highly aggressive form of lung cancer that requires prompt and accurate diagnosis and treatment to improve outcomes.

Also known as: Large cell carcinoma (LCC), malignant large cell carcinoma, and giant cell carcinoma.

SCC typically appears as a firm, flat, or raised bump on the skin, and may be pink, red, or scaly. The cancer cells are usually well-differentiated, meaning they resemble normal squamous cells, but they can grow rapidly and invade surrounding tissues if left untreated.

SCC is more common in fair-skinned individuals and those who spend a lot of time in the sun, as UV radiation can damage the skin cells and increase the risk of cancer. The cancer can also spread to other parts of the body, such as lymph nodes or organs, and can be life-threatening if not treated promptly and effectively.

Treatment for SCC usually involves surgery to remove the cancerous tissue, and may also include radiation therapy or chemotherapy to kill any remaining cancer cells. Early detection and treatment are important to improve outcomes for patients with SCC.

Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:

1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)

The symptoms of adenocarcinoma depend on the location of the cancer and can include:

1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)

The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.

Treatment options for adenocarcinoma depend on the location of the cancer and can include:

1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.

The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.

There are several subtypes of carcinoma, including:

1. Adenocarcinoma: This type of carcinoma originates in glandular cells, which produce fluids or mucus. Examples include breast cancer, prostate cancer, and colon cancer.
2. Squamous cell carcinoma: This type of carcinoma originates in squamous cells, which are found on the surface layers of skin and mucous membranes. Examples include head and neck cancers, cervical cancer, and anal cancer.
3. Basal cell carcinoma: This type of carcinoma originates in the deepest layer of skin, called the basal layer. It is the most common type of skin cancer and tends to grow slowly.
4. Neuroendocrine carcinoma: This type of carcinoma originates in cells that produce hormones and neurotransmitters. Examples include lung cancer, pancreatic cancer, and thyroid cancer.
5. Small cell carcinoma: This type of carcinoma is a highly aggressive form of lung cancer that spreads quickly to other parts of the body.

The signs and symptoms of carcinoma depend on the location and stage of the cancer. Some common symptoms include:

* A lump or mass
* Pain
* Skin changes, such as a new mole or a change in the color or texture of the skin
* Changes in bowel or bladder habits
* Abnormal bleeding

The diagnosis of carcinoma typically involves a combination of imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a small sample of tissue for examination under a microscope. Treatment options for carcinoma depend on the location and stage of the cancer and may include surgery, radiation therapy, chemotherapy, or a combination of these.

In conclusion, carcinoma is a type of cancer that originates in epithelial cells and can occur in various parts of the body. Early detection and treatment are important for improving outcomes.

References:

1. American Cancer Society. (2022). Carcinoma. Retrieved from
2. Mayo Clinic. (2022). Carcinoma. Retrieved from
3. MedlinePlus. (2022). Carcinoma. Retrieved from

There are several risk factors for developing HCC, including:

* Cirrhosis, which can be caused by heavy alcohol consumption, viral hepatitis (such as hepatitis B and C), or fatty liver disease
* Family history of liver disease
* Chronic obstructive pulmonary disease (COPD)
* Diabetes
* Obesity

HCC can be challenging to diagnose, as the symptoms are non-specific and can be similar to those of other conditions. However, some common symptoms of HCC include:

* Yellowing of the skin and eyes (jaundice)
* Fatigue
* Loss of appetite
* Abdominal pain or discomfort
* Weight loss

If HCC is suspected, a doctor may perform several tests to confirm the diagnosis, including:

* Imaging tests, such as ultrasound, CT scan, or MRI, to look for tumors in the liver
* Blood tests to check for liver function and detect certain substances that are produced by the liver
* Biopsy, which involves removing a small sample of tissue from the liver to examine under a microscope

Once HCC is diagnosed, treatment options will depend on several factors, including the stage and location of the cancer, the patient's overall health, and their personal preferences. Treatment options may include:

* Surgery to remove the tumor or parts of the liver
* Ablation, which involves destroying the cancer cells using heat or cold
* Chemoembolization, which involves injecting chemotherapy drugs into the hepatic artery to reach the cancer cells
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of the cancer

Overall, the prognosis for HCC is poor, with a 5-year survival rate of approximately 20%. However, early detection and treatment can improve outcomes. It is important for individuals at high risk for HCC to be monitored regularly by a healthcare provider, and to seek medical attention if they experience any symptoms.

Definition:
A type of cancer that arises from cells of the neuroendocrine system, which are cells that produce hormones and neurotransmitters. These tumors can occur in various parts of the body, such as the lungs, digestive tract, and pancreas. They tend to grow slowly and can produce excess hormones or neurotransmitters, leading to a variety of symptoms. Carcinoma, neuroendocrine tumors are relatively rare but are becoming more commonly diagnosed.

Synonyms:

* Neuroendocrine carcinoma
* Neuroendocrine tumor
* Carcinoid tumor

Note: The term "carcinoma" refers to a type of cancer that arises from epithelial cells, while the term "neuroendocrine" refers to the fact that these tumors originate in cells of the neuroendocrine system.

Translation:

English: Neuroendocrine carcinoma
German: Neuroendokrines Karzinom
French: Tumeur carcinoïde neuroendocrine
Spanish: Carcinoma neuendocrino
Italian: Carcinoma neuroendocrino

Some common types of lung diseases include:

1. Asthma: A chronic condition characterized by inflammation and narrowing of the airways, leading to wheezing, coughing, and shortness of breath.
2. Chronic Obstructive Pulmonary Disease (COPD): A progressive condition that causes chronic inflammation and damage to the airways and lungs, making it difficult to breathe.
3. Pneumonia: An infection of the lungs that can be caused by bacteria, viruses, or fungi, leading to fever, chills, coughing, and difficulty breathing.
4. Bronchiectasis: A condition where the airways are damaged and widened, leading to chronic infections and inflammation.
5. Pulmonary Fibrosis: A condition where the lungs become scarred and stiff, making it difficult to breathe.
6. Lung Cancer: A malignant tumor that develops in the lungs, often caused by smoking or exposure to carcinogens.
7. Cystic Fibrosis: A genetic disorder that affects the respiratory and digestive systems, leading to chronic infections and inflammation in the lungs.
8. Tuberculosis (TB): An infectious disease caused by Mycobacterium Tuberculosis, which primarily affects the lungs but can also affect other parts of the body.
9. Pulmonary Embolism: A blockage in one of the arteries in the lungs, often caused by a blood clot that has traveled from another part of the body.
10. Sarcoidosis: An inflammatory disease that affects various organs in the body, including the lungs, leading to the formation of granulomas and scarring.

These are just a few examples of conditions that can affect the lungs and respiratory system. It's important to note that many of these conditions can be treated with medication, therapy, or surgery, but early detection is key to successful treatment outcomes.

Also known as CIS.

The term "paraneoplastic" refers to the fact that these conditions are parallel to, or associated with, neoplasms (abnormal growths) in the body. The exact cause of paraneoplastic syndromes is not fully understood, but they are believed to be related to the immune system's response to cancer cells.

Some common features of paraneoplastic syndromes include:

1. Autoantibodies: The immune system produces antibodies that attack the body's own tissues and organs.
2. Inflammation: The immune system causes inflammation in various parts of the body.
3. Nerve damage: Paraneoplastic syndromes can affect the nerves, leading to symptoms such as numbness, weakness, and pain.
4. Muscle weakness: Some paraneoplastic syndromes can cause muscle weakness and wasting.
5. Skin rashes: Some patients with paraneoplastic syndromes may develop skin rashes or lesions.
6. Eye problems: Paraneoplastic syndromes can affect the eyes, leading to symptoms such as double vision, blindness, and eye pain.
7. Endocrine dysfunction: Some paraneoplastic syndromes can disrupt the normal functioning of the endocrine system, leading to hormonal imbalances.

Examples of paraneoplastic syndromes include:

1. Lambert-Eaton myasthenic syndrome (LEMS): This is a rare autoimmune disorder that affects the nerves and muscles, leading to muscle weakness and fatigue. It is often associated with small cell lung cancer.
2. Anti-NMDA receptor encephalitis: This is a severe autoimmune disorder that affects the brain and can cause symptoms such as seizures, confusion, and memory loss. It is often associated with ovarian teratoma.
3. Paraneoplastic cerebellar degeneration (PCD): This is a rare condition that affects the cerebellum and can cause symptoms such as coordination problems, balance difficulties, and difficulty with movement. It is often associated with lung cancer or other types of cancer.
4. Stiff-person syndrome: This is a rare autoimmune disorder that affects the central nervous system and can cause symptoms such as muscle stiffness, spasms, and autonomy dysfunction. It is often associated with ovarian teratoma.
5. Polymyositis: This is a rare inflammatory condition that affects the muscles and can cause muscle weakness and wasting. It is often associated with cancer, particularly lung cancer.
6. Dercum's disease: This is a rare condition that affects the adipose tissue and can cause symptoms such as pain, swelling, and limited mobility. It is often associated with cancer, particularly breast cancer.
7. Multiple myeloma: This is a type of cancer that affects the plasma cells in the bone marrow and can cause symptoms such as bone pain, fatigue, and weakness. It is often associated with ovarian teratoma.
8. Painless thyroiditis: This is a rare condition that affects the thyroid gland and can cause symptoms such as thyroid gland inflammation, fatigue, and weight gain. It is often associated with cancer, particularly breast cancer.
9. Ovarian cysts: These are fluid-filled sacs that form on the ovaries and can cause symptoms such as pelvic pain, bloating, and irregular menstrual periods. They are often associated with ovarian teratoma.
10. Endometriosis: This is a condition in which tissue similar to the lining of the uterus grows outside of the uterus and can cause symptoms such as pelvic pain, heavy menstrual bleeding, and infertility. It is often associated with ovarian teratoma.

It's important to note that these conditions are rare and not all cases of ovarian teratoma are associated with them. If you suspect you may have ovarian teratoma, it's important to talk to your healthcare provider for proper diagnosis and treatment.

The risk factors for developing bronchogenic carcinoma include smoking, exposure to secondhand smoke, exposure to radon gas, asbestos, and certain industrial chemicals, as well as a family history of lung cancer. Symptoms of bronchogenic carcinoma can include coughing, chest pain, difficulty breathing, fatigue, weight loss, and coughing up blood.

Bronchogenic carcinoma is diagnosed through a combination of imaging tests such as chest x-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, as well as biopsy. Treatment options for bronchogenic carcinoma can include surgery, radiation therapy, chemotherapy, or a combination of these. The prognosis for bronchogenic carcinoma is generally poor, with a five-year survival rate of about 18%.

Prevention is the best approach to managing bronchogenic carcinoma, and this includes quitting smoking, avoiding exposure to secondhand smoke and other risk factors, and getting regular screenings if you are at high risk. Early detection and treatment can improve survival rates for patients with bronchogenic carcinoma, so it is important to seek medical attention if symptoms persist or worsen over time.

Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.

There are several types of liver neoplasms, including:

1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.

The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.

Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.

Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.

The exact cause of ductal carcinoma is unknown, but certain risk factors such as family history, genetics, hormone replacement therapy, obesity, and delayed childbearing have been linked to its development. Early detection through mammography and breast self-examination can improve survival rates, which are generally high for women diagnosed with this type of cancer if caught early. Treatment typically involves surgery to remove the tumor (lumpectomy or mastectomy), followed by radiation therapy and/or chemotherapy.

Neoplastic metastasis can occur in any type of cancer but are more common in solid tumors such as carcinomas (breast, lung, colon). It is important for cancer diagnosis and prognosis because metastasis indicates that the cancer has spread beyond its original site and may be more difficult to treat.

Metastases can appear at any distant location but commonly found sites include the liver, lungs, bones, brain, and lymph nodes. The presence of metastases indicates a higher stage of cancer which is associated with lower survival rates compared to localized cancer.

BCC usually appears as a flesh-colored or pink bump, often with small blood vessels on the surface. It may also be flat and scaly, or have a waxy appearance. In rare cases, BCC can grow deep into the skin and cause damage to surrounding tissue.

Although BCC is not as aggressive as other types of skin cancer, such as melanoma, it can still cause significant damage if left untreated. Treatment options for BCC include topical creams, surgical excision, and Mohs microscopic surgery.

Preventative measures against BCC include protecting the skin from the sun, using sunscreen with a high SPF, and avoiding prolonged exposure to UV radiation. Early detection and treatment are key in managing this condition.

1. Acute respiratory distress syndrome (ARDS): This is a severe and life-threatening condition that occurs when the lungs become inflamed and fill with fluid, making it difficult to breathe.
2. Pneumonia: This is an infection of the lungs that can cause inflammation and damage to the air sacs and lung tissue.
3. Aspiration pneumonitis: This occurs when food, liquid, or other foreign substances are inhaled into the lungs, causing inflammation and damage.
4. Chemical pneumonitis: This is caused by exposure to harmful chemicals or toxins that can damage the lungs and cause inflammation.
5. Radiation pneumonitis: This occurs when the lungs are exposed to high levels of radiation, causing damage and inflammation.
6. Lung fibrosis: This is a chronic condition in which the lungs become scarred and stiff, making it difficult to breathe.
7. Pulmonary embolism: This occurs when a blood clot forms in the lungs, blocking the flow of blood and oxygen to the heart and other organs.

Symptoms of lung injury can include:

* Shortness of breath
* Chest pain or tightness
* Coughing up blood or pus
* Fever
* Confusion or disorientation

Treatment for lung injury depends on the underlying cause and severity of the condition, and may include oxygen therapy, medications to reduce inflammation, antibiotics for infections, and mechanical ventilation in severe cases. In some cases, lung injury can be a life-threatening condition and may require hospitalization and intensive care.

1. Tumor size and location: Larger tumors that have spread to nearby tissues or organs are generally considered more invasive than smaller tumors that are confined to the original site.
2. Cellular growth patterns: The way in which cancer cells grow and divide can also contribute to the overall invasiveness of a neoplasm. For example, cells that grow in a disorganized or chaotic manner may be more likely to invade surrounding tissues.
3. Mitotic index: The mitotic index is a measure of how quickly the cancer cells are dividing. A higher mitotic index is generally associated with more aggressive and invasive cancers.
4. Necrosis: Necrosis, or the death of cells, can be an indication of the level of invasiveness of a neoplasm. The presence of significant necrosis in a tumor is often a sign that the cancer has invaded surrounding tissues and organs.
5. Lymphovascular invasion: Cancer cells that have invaded lymphatic vessels or blood vessels are considered more invasive than those that have not.
6. Perineural invasion: Cancer cells that have invaded nerve fibers are also considered more invasive.
7. Histological grade: The histological grade of a neoplasm is a measure of how abnormal the cancer cells look under a microscope. Higher-grade cancers are generally considered more aggressive and invasive than lower-grade cancers.
8. Immunohistochemical markers: Certain immunohistochemical markers, such as Ki-67, can be used to evaluate the proliferative activity of cancer cells. Higher levels of these markers are generally associated with more aggressive and invasive cancers.

Overall, the degree of neoplasm invasiveness is an important factor in determining the likelihood of the cancer spreading to other parts of the body (metastasizing) and in determining the appropriate treatment strategy for the patient.

Lymphatic metastasis occurs when cancer cells enter the lymphatic vessels and are carried through the lymphatic system to other parts of the body. This can happen through several mechanisms, including:

1. Direct invasion: Cancer cells can invade the nearby lymphatic vessels and spread through them.
2. Lymphatic vessel embolization: Cancer cells can block the flow of lymphatic fluid and cause the formation of a clot-like structure, which can trap cancer cells and allow them to grow.
3. Lymphatic vessel invasion: Cancer cells can infiltrate the walls of lymphatic vessels and spread through them.

Lymphatic metastasis is a common mechanism for the spread of cancer, particularly in the breast, melanoma, and other cancers that have a high risk of lymphatic invasion. The presence of lymphatic metastasis in a patient's body can indicate a more aggressive cancer and a poorer prognosis.

Treatment for lymphatic metastasis typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery may be used to remove any affected lymph nodes or other tumors that have spread through the lymphatic system. Chemotherapy may be used to kill any remaining cancer cells, while radiation therapy may be used to shrink the tumors and relieve symptoms.

In summary, lymphatic metastasis is a common mechanism for the spread of cancer through the body, particularly in cancers that originate in organs with a high lymphatic drainage. Treatment typically involves a combination of surgery, chemotherapy, and radiation therapy to remove or shrink the tumors and relieve symptoms.

This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.

Types of Bronchial Neoplasms:

1. Adenocarcinoma: This is the most common type of lung cancer and accounts for approximately 40% of all lung cancers. It originates in the glandular cells that line the bronchi.
2. Squamous Cell Carcinoma: This type of lung cancer originates in the squamous cells that line the bronchi. It is the second most common type of lung cancer, accounting for approximately 25% of all lung cancers.
3. Small Cell Lung Cancer (SCLC): This type of lung cancer is highly aggressive and accounts for approximately 10% of all lung cancers. It originates in the small cells that line the bronchi.
4. Large Cell Carcinoma: This type of lung cancer is rare and accounts for approximately 5% of all lung cancers. It originates in the large cells that line the bronchi.
5. Bronchioloalveolar Carcinoma (BAC): This type of lung cancer originates in the small air sacs (alveoli) and is rare, accounting for approximately 2% of all lung cancers.
6. Lymphoma: This type of cancer originates in the immune system cells that line the bronchi. It is rare, accounting for approximately 1% of all lung cancers.
7. Carcinoid Tumors: These are rare types of lung cancer that originate in the neuroendocrine cells that line the bronchi. They are typically slow-growing and less aggressive than other types of lung cancer.
8. Secondary Cancers: These are cancers that have spread to the lungs from other parts of the body, such as breast cancer or colon cancer.

Diagnosis of Bronchial Neoplasms:

1. Medical History and Physical Examination: A thorough medical history and physical examination are essential for diagnosing bronchial neoplasms. The doctor will ask questions about the patient's symptoms, risk factors, and medical history.
2. Chest X-Ray: A chest X-ray is often the first diagnostic test performed to evaluate the lungs for any abnormalities.
3. Computed Tomography (CT) Scan: A CT scan is a more detailed imaging test that uses X-rays and computer technology to produce cross-sectional images of the lungs. It can help identify the size, location, and extent of the tumor.
4. Positron Emission Tomography (PET) Scan: A PET scan is a diagnostic test that uses small amounts of radioactive material to visualize the metabolic activity of the cells in the lungs. It can help identify the presence of cancerous cells and determine the effectiveness of treatment.
5. Biopsy: A biopsy involves taking a sample of tissue from the lung and examining it under a microscope for cancerous cells. It is a definitive diagnostic test for bronchial neoplasms.
6. Bronchoscopy: Bronchoscopy is a procedure in which a thin, flexible tube with a camera on the end is inserted through the nose or mouth and guided to the lungs. It can help identify any abnormalities in the airways and obtain a biopsy sample.
7. Magnetic Resonance Imaging (MRI): An MRI uses magnetic fields and radio waves to produce detailed images of the lungs and surrounding tissues. It is not as commonly used for diagnosing bronchial neoplasms as other imaging tests, but it may be recommended in certain cases.
8. Ultrasound: An ultrasound uses high-frequency sound waves to produce images of the lungs and surrounding tissues. It is not typically used as a diagnostic test for bronchial neoplasms, but it may be used to evaluate the spread of cancer to other parts of the body.

It's important to note that the specific diagnostic tests and procedures used will depend on the individual case and the suspicion of malignancy. Your doctor will discuss the best course of action with you based on your symptoms, medical history, and test results.

Carcinoid tumors are usually found in the appendix, small intestine, rectum, or other parts of the gastrointestinal tract. They can also occur in the lungs, pancreas, or other organs. These tumors tend to grow slowly and often do not cause any symptoms until they have grown quite large.

Carcinoid tumors are diagnosed through a combination of imaging tests such as CT scans, MRI scans, and endoscopies, along with a biopsy to confirm the presence of cancer cells. Treatment for carcinoid tumors depends on the location, size, and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these.

Some of the symptoms that may be associated with carcinoid tumors include:

* Flushing (redness and warmth of the skin)
* Wheezing
* Shortness of breath
* Abdominal pain
* Diarrhea
* Weight loss

Carcinoid tumors are relatively rare, accounting for only about 1% to 5% of all cancer cases. However, they tend to be more common in certain parts of the world, such as North America and Europe. The exact cause of carcinoid tumors is not known, but they are thought to be linked to genetic mutations that occur during fetal development.

Overall, while carcinoid tumors are rare and can be challenging to diagnose and treat, advances in medical technology and cancer research have improved the outlook for patients with these types of tumors. With early detection and appropriate treatment, many people with carcinoid tumors can achieve long-term survival and a good quality of life.

The symptoms of LEMS typically develop gradually over time and may include:

1. Muscle weakness that worsens with activity and improves with rest.
2. Weakness in the legs, hips, and shoulders.
3. Fatigue and muscle cramps.
4. Difficulty walking or standing upright.
5. Double vision or other eye problems.
6. Dry mouth and difficulty swallowing.
7. Increased heart rate and blood pressure.
8. Impaired reflexes.
9. Decreased sweating.
10. Weight loss.

The exact cause of LEMS is not known, but it is believed to be an autoimmune disorder in which the immune system mistakenly attacks the VGCCs in the neuromuscular junction. The condition is often associated with other autoimmune disorders such as thyroiditis, vitiligo, and adrenal insufficiency.

There is no cure for LEMS, but treatment options are available to manage the symptoms. These may include:

1. Immunosuppressive medications such as prednisone to reduce inflammation and suppress the immune system.
2. Intracranial pressure-lowering medications such as acetazolamide to reduce the pressure in the brain.
3. Muscle strengthening exercises to improve muscle function.
4. Physical therapy to maintain muscle strength and flexibility.
5. Orthostatic hypotension medications to manage orthostatic hypotension (a drop in blood pressure when standing).
6. Pain management medications to relieve muscle cramps, spasms, or pain.
7. Nutritional support to ensure adequate nutrition and prevent weight loss.
8. Respiratory support as needed to manage respiratory muscle weakness.
9. Speech therapy to improve communication skills.
10. Psychological support to cope with the emotional and social challenges of the condition.

It is important for individuals with LEMS to work closely with their healthcare team to manage their symptoms and prevent complications. With proper treatment, many people with LEMS can lead active and fulfilling lives.

Transitional cell carcinoma typically affects older adults, with the average age at diagnosis being around 70 years. Men are more likely to be affected than women, and the risk of developing TCC increases with age and exposure to certain environmental factors such as smoking and exposure to certain chemicals.

The symptoms of TCC can vary depending on the location and stage of the cancer, but may include:

* Blood in the urine (hematuria)
* Painful urination
* Frequent urination
* Pain in the lower abdomen or back

If left untreated, TCC can spread to other parts of the body, including the lymph nodes, liver, and bones. Treatment options for TCC may include surgery, chemotherapy, and immunotherapy, and the prognosis depends on the stage and location of the cancer at the time of diagnosis.

Preventive measures to reduce the risk of developing TCC include maintaining a healthy diet and lifestyle, avoiding smoking and excessive alcohol consumption, and regular screening for bladder cancer. Early detection and treatment can improve the prognosis for patients with TCC.

There are different types of Breast Neoplasms such as:

1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.

2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.

3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.

4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.

5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.

Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.

Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.

It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.

Example Sentences:

The patient was diagnosed with adenosquamous carcinoma of the lung and underwent surgical resection.

The pathology report revealed that the tumor was an adenosquamous carcinoma, which is a rare type of lung cancer.

Note: Adenosquamous carcinoma is a rare subtype of non-small cell lung cancer (NSCLC), accounting for approximately 1-3% of all lung cancers. It has a more aggressive clinical course and poorer prognosis compared to other types of NSCLC.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

MCC typically affects older adults, with most cases occurring in people over the age of 60. The disease is more common in fair-skinned individuals, especially those who have had prolonged exposure to the sun. MCC can occur anywhere on the body, but it is most commonly found on the face, neck, and arms.

The symptoms of MCC can vary depending on the location and size of the tumor, but they may include:

* A firm, shiny nodule or lump on the skin
* Painless lumps or swelling in the affected area
* Redness, scaliness, or oozing of the skin around the nodule
* Itching or burning sensations in the affected area

If MCC is suspected, a biopsy will be performed to confirm the diagnosis. Treatment for MCC typically involves surgery to remove the tumor and any affected tissue. In some cases, radiation therapy or chemotherapy may also be recommended to kill any remaining cancer cells.

The prognosis for MCC is generally poor, as it tends to be an aggressive disease that can spread quickly to other parts of the body. However, early detection and treatment can improve the chances of a successful outcome.

Intraductal carcinoma may or may not cause symptoms, and is usually detected by a mammogram. Treatment often involves surgery to remove the cancerous cells from the milk ducts. If left untreated, intraductal carcinoma may progress to more advanced breast cancer in some cases.

Intraductal carcinoma accounts for 20% of all breast cancers diagnosed each year in the United States, according to estimates from the American Cancer Society. The condition affects women of all ages, but is most common in postmenopausal women.

This cancer is known for its aggressive behavior and early metastasis to regional lymph nodes, bones, and distant organs such as the liver and lungs. The prognosis is generally poor, with a 5-year survival rate of about 50%. The treatment options include surgery, radiation therapy, and chemotherapy, and the choice of treatment depends on the stage and location of the tumor.

Adenoid cystic carcinoma is also known as adenoid cystic cancer, cylindromatosis, or basaloid squamous cell carcinoma. It is a rare malignancy that requires specialized knowledge and management by head and neck surgeons and oncologists.

Characteristics of Medullary Carcinoma:

1. Location: Medullary carcinoma typically arises in the inner substance of the breast, near the milk ducts and blood vessels.
2. Growth pattern: The cancer cells grow in a nodular or sheet-like pattern, with a clear boundary between the tumor and the surrounding normal tissue.
3. Cellular features: The cancer cells are typically large and polygonal, with prominent nucleoli and a pale, pinkish cytoplasm.
4. Lymphocytic infiltration: There is often a significant amount of lymphocytic infiltration surrounding the tumor, which can give it a "spiculated" or "heterogeneous" appearance.
5. Grade: Medullary carcinoma is generally a low-grade cancer, meaning that the cells are slow-growing and less aggressive than those of other types of breast cancer.
6. Hormone receptors: Medullary carcinoma is often hormone receptor-positive, meaning that the cancer cells have estrogen or progesterone receptors on their surface.
7. Her2 status: The cancer cells are typically Her2-negative, meaning that they do not overexpress the Her2 protein.

Prognosis and Treatment of Medullary Carcinoma:

The prognosis for medullary carcinoma is generally good, as it tends to be a slow-growing and less aggressive type of breast cancer. The 5-year survival rate for medullary carcinoma is around 80-90%.

Treatment for medullary carcinoma typically involves surgery, such as a lumpectomy or mastectomy, followed by radiation therapy and/or hormone therapy. Chemotherapy is sometimes used in addition to these treatments, especially if the cancer has spread to the lymph nodes or other parts of the body.

It's important for women with medullary carcinoma to work closely with their healthcare team to develop a personalized treatment plan that takes into account their unique needs and circumstances. With appropriate treatment, many women with medullary carcinoma can achieve long-term survival and a good quality of life.

The symptoms of ALI can vary depending on the severity of the condition, but may include:

* Shortness of breath (dyspnea)
* Chest pain or tightness (pleurisy)
* Cough, which may produce mucus or pus
* Fatigue, confusion, or disorientation
* Low oxygen levels in the blood (hypoxia)

If left untreated, ALI can progress to a more severe condition called acute respiratory distress syndrome (ARDS), which can be fatal. Treatment for ALI typically involves supportive care, such as mechanical ventilation, medications to manage inflammation and fluid buildup in the lungs, and management of underlying causes. In severe cases, extracorporeal membrane oxygenation (ECMO) or lung transplantation may be necessary.

It's important to note that ALI can occur in people of all ages and can be caused by a variety of factors, so it's important to seek medical attention right away if you or someone you know is experiencing symptoms of the condition.

Carcinoma, lobular (also known as lobular carcinoma in situ or LCIS) is a type of cancer that originates in the milk-producing glands (lobules) of the breast. It is a precancerous condition that can progress to invasive breast cancer if left untreated.

Precancerous changes occur within the lobules, leading to an abnormal growth of cells that can eventually break through the basement membrane and invade surrounding tissues. The risk of developing invasive breast cancer is increased in individuals with LCIS, especially if there are multiple areas of involvement.

Diagnosis is typically made through a combination of clinical breast examination, mammography, and histopathological analysis of a biopsy sample. Treatment options for LCIS include close surveillance, surgery, or radiation therapy, depending on the extent of the condition and the individual patient's risk factors.

Medical Specialty:

The medical specialty that deals with carcinoma, lobular is breast surgical oncology. Breast surgical oncologists are trained to diagnose and treat all types of breast cancer, including ductal and lobular carcinomas. They work in collaboration with other healthcare professionals, such as radiation oncologists and medical oncologists, to develop a comprehensive treatment plan for each patient.

Other relevant information:

* Lobular carcinoma in situ (LCIS) is a precancerous condition that affects the milk-producing glands (lobules) of the breast.
* It is estimated that 10-15% of all breast cancers are derived from LCIS.
* Women with a history of LCIS have a higher risk of developing invasive breast cancer in the future.
* The exact cause of LCIS is not fully understood, but it is thought to be linked to hormonal and genetic factors.

There are several types of thyroid neoplasms, including:

1. Thyroid nodules: These are abnormal growths or lumps that can develop in the thyroid gland. Most thyroid nodules are benign (non-cancerous), but some can be malignant (cancerous).
2. Thyroid cancer: This is a type of cancer that develops in the thyroid gland. There are several types of thyroid cancer, including papillary, follicular, and medullary thyroid cancer.
3. Thyroid adenomas: These are benign tumors that develop in the thyroid gland. They are usually non-cancerous and do not spread to other parts of the body.
4. Thyroid cysts: These are fluid-filled sacs that can develop in the thyroid gland. They are usually benign and do not cause any symptoms.

Thyroid neoplasms can be caused by a variety of factors, including genetic mutations, exposure to radiation, and certain medical conditions, such as thyroiditis (inflammation of the thyroid gland).

Symptoms of thyroid neoplasms can include:

* A lump or swelling in the neck
* Pain in the neck or throat
* Difficulty swallowing or breathing
* Hoarseness or voice changes
* Weight loss or fatigue

Diagnosis of thyroid neoplasms usually involves a combination of physical examination, imaging tests (such as ultrasound or CT scans), and biopsies. Treatment depends on the type and severity of the neoplasm, and can include surgery, radiation therapy, and medications.

Small cell sarcoma typically affects the extremities (arms or legs) and can cause symptoms such as pain, swelling, and limited mobility. The diagnosis of small cell sarcoma is based on a combination of imaging studies (such as X-rays, CT scans, or MRI) and a biopsy, where a sample of tissue is removed and examined under a microscope for cancer cells.

Treatment for small cell sarcoma usually involves a combination of surgery, chemotherapy, and radiation therapy. The prognosis for this type of cancer depends on the stage and location of the tumor, as well as the effectiveness of treatment.

Brain neoplasms can arise from various types of cells in the brain, including glial cells (such as astrocytes and oligodendrocytes), neurons, and vascular tissues. The symptoms of brain neoplasms vary depending on their size, location, and type, but may include headaches, seizures, weakness or numbness in the limbs, and changes in personality or cognitive function.

There are several different types of brain neoplasms, including:

1. Meningiomas: These are benign tumors that arise from the meninges, the thin layers of tissue that cover the brain and spinal cord.
2. Gliomas: These are malignant tumors that arise from glial cells in the brain. The most common type of glioma is a glioblastoma, which is aggressive and hard to treat.
3. Pineal parenchymal tumors: These are rare tumors that arise in the pineal gland, a small endocrine gland in the brain.
4. Craniopharyngiomas: These are benign tumors that arise from the epithelial cells of the pituitary gland and the hypothalamus.
5. Medulloblastomas: These are malignant tumors that arise in the cerebellum, specifically in the medulla oblongata. They are most common in children.
6. Acoustic neurinomas: These are benign tumors that arise on the nerve that connects the inner ear to the brain.
7. Oligodendrogliomas: These are malignant tumors that arise from oligodendrocytes, the cells that produce the fatty substance called myelin that insulates nerve fibers.
8. Lymphomas: These are cancers of the immune system that can arise in the brain and spinal cord. The most common type of lymphoma in the CNS is primary central nervous system (CNS) lymphoma, which is usually a type of B-cell non-Hodgkin lymphoma.
9. Metastatic tumors: These are tumors that have spread to the brain from another part of the body. The most common types of metastatic tumors in the CNS are breast cancer, lung cancer, and melanoma.

These are just a few examples of the many types of brain and spinal cord tumors that can occur. Each type of tumor has its own unique characteristics, such as its location, size, growth rate, and biological behavior. These factors can help doctors determine the best course of treatment for each patient.

Types of Esophageal Neoplasms:

1. Barrett's Esophagus: This is a precancerous condition that occurs when the cells lining the esophagus undergo abnormal changes, increasing the risk of developing esophageal cancer.
2. Adenocarcinoma: This is the most common type of esophageal cancer, accounting for approximately 70% of all cases. It originates in the glands that line the esophagus.
3. Squamous Cell Carcinoma: This type of cancer accounts for about 20% of all esophageal cancers and originates in the squamous cells that line the esophagus.
4. Other rare types: Other rare types of esophageal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Causes and Risk Factors:

1. Gastroesophageal reflux disease (GERD): Long-standing GERD can lead to the development of Barrett's esophagus, which is a precancerous condition that increases the risk of developing esophageal cancer.
2. Obesity: Excess body weight is associated with an increased risk of developing esophageal cancer.
3. Diet: A diet high in processed meats and low in fruits and vegetables may increase the risk of developing esophageal cancer.
4. Alcohol consumption: Heavy alcohol consumption is a known risk factor for esophageal cancer.
5. Smoking: Cigarette smoking is a major risk factor for esophageal cancer.
6. Family history: Having a family history of esophageal cancer or other cancers may increase an individual's risk.
7. Age: The risk of developing esophageal cancer increases with age, with most cases occurring in people over the age of 50.
8. Other medical conditions: Certain medical conditions, such as achalasia, may increase the risk of developing esophageal cancer.

Symptoms and Diagnosis:

1. Dysphagia (difficulty swallowing): This is the most common symptom of esophageal cancer, and can be caused by a narrowing or blockage of the esophagus due to the tumor.
2. Chest pain or discomfort: Pain in the chest or upper back can be a symptom of esophageal cancer.
3. Weight loss: Losing weight without trying can be a symptom of esophageal cancer.
4. Coughing or hoarseness: If the tumor is obstructing the airway, it can cause coughing or hoarseness.
5. Fatigue: Feeling tired or weak can be a symptom of esophageal cancer.
6. Diagnosis: A diagnosis of esophageal cancer is typically made through a combination of endoscopy, imaging tests (such as CT scans), and biopsies.

Treatment Options:

1. Surgery: Surgery is the primary treatment for esophageal cancer, and can involve removing the tumor and some surrounding tissue, or removing the entire esophagus and replacing it with a section of stomach or intestine.
2. Chemotherapy: Chemotherapy involves using drugs to kill cancer cells, and is often used in combination with surgery to treat esophageal cancer.
3. Radiation therapy: Radiation therapy uses high-energy X-rays to kill cancer cells, and can be used alone or in combination with surgery or chemotherapy.
4. Targeted therapy: Targeted therapy drugs are designed to target specific molecules that are involved in the growth and spread of cancer cells, and can be used in combination with other treatments.

Prognosis and Survival Rate:

1. The prognosis for esophageal cancer is generally poor, with a five-year survival rate of around 20%.
2. Factors that can improve the prognosis include early detection, small tumor size, and absence of spread to lymph nodes or other organs.
3. The overall survival rate for esophageal cancer has not improved much over the past few decades, but advances in treatment have led to a slight increase in survival time for some patients.

Lifestyle Changes and Prevention:

1. Avoiding tobacco and alcohol: Tobacco and alcohol are major risk factors for esophageal cancer, so avoiding them can help reduce the risk of developing the disease.
2. Maintaining a healthy diet: Eating a balanced diet that is high in fruits, vegetables, and whole grains can help protect against esophageal cancer.
3. Managing obesity: Obesity is a risk factor for esophageal cancer, so maintaining a healthy weight through diet and exercise can help reduce the risk of developing the disease.
4. Reducing exposure to pollutants: Exposure to certain chemicals and pollutants, such as pesticides and asbestos, has been linked to an increased risk of esophageal cancer. Avoiding these substances can help reduce the risk of developing the disease.
5. Getting regular screening: Regular screening for Barrett's esophagus, a precancerous condition that can develop in people with gastroesophageal reflux disease (GERD), can help detect and treat esophageal cancer early, when it is most treatable.

Current Research and Future Directions:

1. Targeted therapies: Researchers are working on developing targeted therapies that can specifically target the genetic mutations that drive the growth of esophageal cancer cells. These therapies may be more effective and have fewer side effects than traditional chemotherapy.
2. Immunotherapy: Immunotherapy, which uses the body's immune system to fight cancer, is being studied as a potential treatment for esophageal cancer. Researchers are working on developing vaccines and other immunotherapies that can help the body recognize and attack cancer cells.
3. Precision medicine: With the help of advanced genomics and precision medicine, researchers are working to identify specific genetic mutations that drive the growth of esophageal cancer in each patient. This information can be used to develop personalized treatment plans that are tailored to the individual patient's needs.
4. Early detection: Researchers are working on developing new methods for early detection of esophageal cancer, such as using machine learning algorithms to analyze medical images and detect signs of cancer at an early stage.
5. Lifestyle modifications: Studies have shown that lifestyle modifications, such as quitting smoking and maintaining a healthy diet, can help reduce the risk of developing esophageal cancer. Researchers are working on understanding the specific mechanisms by which these modifications can help prevent the disease.

In conclusion, esophageal cancer is a complex and aggressive disease that is often diagnosed at an advanced stage. However, with advances in technology, research, and treatment options, there is hope for improving outcomes for patients with this disease. By understanding the risk factors, early detection methods, and current treatments, as well as ongoing research and future directions, we can work towards a future where esophageal cancer is more manageable and less deadly.

Most nasopharyngeal neoplasms are rare and tend to affect children and young adults more frequently than older adults. The most common types of nasopharyngeal neoplasms include:

1. Nasopharyngeal carcinoma (NPC): This is the most common type of malignant nasopharyngeal neoplasm and tends to affect young adults in Southeast Asia more frequently than other populations.
2. Adenoid cystic carcinoma: This is a rare, slow-growing tumor that usually affects the nasopharynx and salivary glands.
3. Metastatic squamous cell carcinoma: This is a type of cancer that originates in another part of the body (usually the head and neck) and spreads to the nasopharynx.
4. Lymphoma: This is a type of cancer that affects the immune system and can occur in the nasopharynx.
5. Benign tumors: These include benign growths such as papillomas, fibromas, and meningiomas.

Symptoms of nasopharyngeal neoplasms can vary depending on the size and location of the tumor but may include:

* Difficulty swallowing
* Nosebleeds
* Headaches
* Facial pain or numbness
* Trouble breathing through the nose
* Hoarseness or voice changes
* Enlarged lymph nodes in the neck

Diagnosis of nasopharyngeal neoplasms usually involves a combination of imaging tests such as CT or MRI scans, endoscopy (insertion of a flexible tube with a camera into the nose and throat), and biopsy (removal of a small sample of tissue for examination under a microscope).

Treatment of nasopharyngeal neoplasms depends on the type, size, location, and stage of the tumor but may include:

* Surgery to remove the tumor
* Radiation therapy to kill cancer cells
* Chemotherapy to kill cancer cells
* Targeted therapy to attack specific molecules on cancer cells

Prognosis for nasopharyngeal neoplasms varies depending on the type and stage of the tumor but in general, early detection and treatment improve the chances of a successful outcome.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

PCD typically affects adults between the ages of 30 and 70 years old and is more common in women than men. The exact cause of PCD is not fully understood, but it is thought to be an autoimmune response, where the immune system mistakenly attacks healthy cells in the cerebellum.

The diagnosis of PCD is based on a combination of clinical features, laboratory tests, and imaging studies. Laboratory tests may include blood tests to look for antineuronal antibodies and cerebrospinal fluid (CSF) analysis to rule out other causes of cerebellar degeneration. Imaging studies, such as MRI or CT scans, may be used to confirm the diagnosis and assess the progression of the disease.

Treatment for PCD is primarily focused on managing the symptoms and improving quality of life. This may include physical therapy, occupational therapy, and speech therapy to help with coordination, balance, and communication. In some cases, medications such as steroids or immunosuppressive drugs may be used to reduce inflammation and slow the progression of the disease.

Prognosis for PCD is generally poor, with a median survival time of around 2-3 years after diagnosis. However, some individuals with PCD may experience a more benign course of the disease, while others may experience a rapid decline in health. The exact prognostic factors for PCD are not fully understood and require further research.

Multiple primary neoplasms can arise in different organs or tissues throughout the body, such as the breast, colon, prostate, lung, or skin. Each tumor is considered a separate entity, with its own unique characteristics, including size, location, and aggressiveness. Treatment for multiple primary neoplasms typically involves surgery, chemotherapy, radiation therapy, or a combination of these modalities.

The diagnosis of multiple primary neoplasms can be challenging due to the overlapping symptoms and radiological findings between the different tumors. Therefore, it is essential to have a thorough clinical evaluation and diagnostic workup to rule out other possible causes of the symptoms and confirm the presence of multiple primary neoplasms.

Multiple primary neoplasms are more common than previously thought, with an estimated prevalence of 2% to 5% in some populations. The prognosis for patients with multiple primary neoplasms varies depending on the location, size, and aggressiveness of each tumor, as well as the patient's overall health status.

It is important to note that multiple primary neoplasms are not the same as metastatic cancer, in which a single primary tumor spreads to other parts of the body. Multiple primary neoplasms are distinct tumors that arise independently from different primary sites within the body.

Benign ovarian neoplasms include:

1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.

Malignant ovarian neoplasms include:

1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.

Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.

These tumors can be benign or malignant, and their growth and behavior vary depending on the type of cancer. Malignant tumors can invade the surrounding tissues and spread to other parts of the body through the bloodstream or lymphatic system, causing serious complications and potentially life-threatening consequences.

The risk factors for developing urinary bladder neoplasms include smoking, exposure to certain chemicals, recurrent bladder infections, and a family history of bladder cancer. The symptoms of these tumors can include blood in the urine, pain during urination, frequent urination, and abdominal pain.

Diagnosis of urinary bladder neoplasms is typically made through a combination of imaging tests such as ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI), and cystoscopy, which involves inserting a flexible tube with a camera into the bladder to visualize the tumor.

Treatment options for urinary bladder neoplasms depend on the type of cancer, stage, and location of the tumor. Treatment may include surgery to remove the tumor, chemotherapy, radiation therapy, or a combination of these modalities. Early detection and treatment can improve the prognosis for patients with urinary bladder neoplasms.

A more detailed explanation of Inappropriate ADH Syndrome may be as follows:

Inappropriate ADH syndrome is a rare endocrine disorder characterized by excessive antidiuretic hormone (ADH) secretion, leading to water retention and hyponatremia. Hyponatremia occurs when the body contains too much water and not enough sodium, causing an imbalance in the electrolyte levels of the blood. This condition can be caused by various factors such as a tumor or other abnormality that increases ADH production or decreases sodium levels in the body. Symptoms of Inappropriate ADH syndrome may include headaches, nausea, vomiting, seizures, and in severe cases, coma.

If left untreated, Inappropriate ADH Syndrome can lead to more serious complications such as seizures or coma. Treatment options for this condition typically involve surgery, radiation therapy, or medication to remove the tumor or other abnormality causing the excessive ADH production and restore sodium levels in the body. It is important to seek medical attention if symptoms persist or worsen over time as early diagnosis and treatment can improve the chances of a successful outcome for this condition.

In summary, Inappropriate ADH Syndrome is an uncommon endocrine disorder caused by excessive ADH secretion leading to hyponatremia due to water retention, which can cause severe symptoms such as headache, nausea, vomiting, seizures, and coma if left untreated. Treatment options involve surgery, radiation therapy, or medication to remove the tumor or other abnormality causing excessive ADH production and restore sodium levels in the body. Early diagnosis and treatment are crucial for a successful outcome.

Some common types of head and neck neoplasms include:

1. Oral cavity cancer: Cancer that develops in the mouth, tongue, lips, or floor of the mouth.
2. Oropharyngeal cancer: Cancer that develops in the throat, including the base of the tongue, soft palate, and tonsils.
3. Hypopharyngeal cancer: Cancer that develops in the lower part of the throat, near the esophagus.
4. Laryngeal cancer: Cancer that develops in the voice box (larynx).
5. Paranasal sinus cancer: Cancer that develops in the air-filled cavities around the eyes and nose.
6. Salivary gland cancer: Cancer that develops in the salivary glands, which produce saliva to moisten food and keep the mouth lubricated.
7. Thyroid gland cancer: Cancer that develops in the butterfly-shaped gland in the neck that regulates metabolism and growth.

The risk factors for developing head and neck neoplasms include tobacco use, heavy alcohol consumption, human papillomavirus (HPV) infection, poor diet, and exposure to environmental carcinogens such as asbestos or radiation. Symptoms of head and neck neoplasms can vary depending on the location and size of the tumor, but may include a lump or swelling, pain, difficulty swallowing, bleeding, and changes in voice or breathing.

Diagnosis of head and neck neoplasms typically involves a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy to confirm the presence of cancer cells. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, depending on the type, location, and stage of the cancer.

Overall, head and neck neoplasms can have a significant impact on quality of life, and early detection and treatment are important for improving outcomes. If you suspect any changes in your head or neck, it is essential to consult with a healthcare professional for an accurate diagnosis and appropriate treatment.

The cancer cells of this type are thought to arise from abnormalities in the cells that line the ducts of the salivary glands. These abnormal cells grow and divide uncontrollably, forming a mass that can obstruct the flow of saliva and cause symptoms such as pain, swelling, and difficulty eating or speaking.

Mucoepidermoid carcinoma is typically diagnosed with a combination of imaging studies, such as CT scans, MRI, and PET scans, and a biopsy, where a sample of tissue is removed from the tumor and examined under a microscope for cancer cells. Treatment typically involves surgery to remove the tumor, followed by radiation therapy and/or chemotherapy to kill any remaining cancer cells.

Prognosis for this type of cancer is generally good if it is diagnosed early and treated promptly, but it can be challenging to treat if it has spread to other parts of the body.

NETs can be benign (non-cancerous) or malignant (cancerous). Malignant NETs can spread to other parts of the body through a process called metastasis, which can lead to serious health complications.

The symptoms of NETs vary depending on their location and size, but may include:

* Abdominal pain or discomfort
* Diarrhea or constipation
* Fatigue
* Weakness
* Shortness of breath
* Skin changes such as flushing or sweating
* Headaches
* Seizures

The diagnosis of NETs is based on a combination of imaging tests such as CT scans, MRI scans, and PET scans, as well as biopsy samples. Treatment options for NETs depend on the type, size, location, and stage of the tumor, but may include:

* Medications to slow or stop hormone production
* Chemotherapy to shrink the tumor
* Radiation therapy to kill cancer cells
* Surgery to remove the tumor

Overall, NETs are rare and can be challenging to diagnose and treat. However, with advances in medical technology and ongoing research, there are more effective treatment options available for patients with NETs.

There are several types of skin neoplasms, including:

1. Basal cell carcinoma (BCC): This is the most common type of skin cancer, and it usually appears as a small, fleshy bump or a flat, scaly patch. BCC is highly treatable, but if left untreated, it can grow and invade surrounding tissue.
2. Squamous cell carcinoma (SCC): This type of skin cancer is less common than BCC but more aggressive. It typically appears as a firm, flat, or raised bump on sun-exposed areas. SCC can spread to other parts of the body if left untreated.
3. Melanoma: This is the most serious type of skin cancer, accounting for only 1% of all skin neoplasms but responsible for the majority of skin cancer deaths. Melanoma can appear as a new or changing mole, and it's essential to recognize the ABCDE signs (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolving size, shape, or color) to detect it early.
4. Sebaceous gland carcinoma: This rare type of skin cancer originates in the oil-producing glands of the skin and can appear as a firm, painless nodule on the forehead, nose, or other oily areas.
5. Merkel cell carcinoma: This is a rare and aggressive skin cancer that typically appears as a firm, shiny bump on the skin. It's more common in older adults and those with a history of sun exposure.
6. Cutaneous lymphoma: This type of cancer affects the immune system and can appear as a rash, nodules, or tumors on the skin.
7. Kaposi sarcoma: This is a rare type of skin cancer that affects people with weakened immune systems, such as those with HIV/AIDS. It typically appears as a flat, red or purple lesion on the skin.

While skin cancers are generally curable when detected early, it's important to be aware of your skin and notice any changes or unusual spots, especially if you have a history of sun exposure or other risk factors. If you suspect anything suspicious, see a dermatologist for an evaluation and potential biopsy. Remember, prevention is key to avoiding the harmful effects of UV radiation and reducing your risk of developing skin cancer.

The tumor cells are typically small, uniform, and well-differentiated, with a distinct cell border and a central nucleus. The tumor cells are often arranged in a glandular or tubular pattern, which is characteristic of this type of cancer.

Carcinoma, Lewis lung usually affects older adults, with the median age at diagnosis being around 60 years. Men are slightly more likely to be affected than women. The main risk factor for developing this type of cancer is smoking, although it can also occur in people who have never smoked.

The symptoms of Carcinoma, Lewis lung can vary depending on the location and size of the tumor, but they may include:

* Chest pain or discomfort
* Coughing up blood
* Shortness of breath
* Fatigue
* Weight loss

If you suspect you may have Carcinoma, Lewis lung or are experiencing any of these symptoms, it is important to consult a healthcare professional for an accurate diagnosis and appropriate treatment.

The post Definition of 'Carcinoma, Lewis Lung' in the medical field appeared first on Healthy Life Tips.

The exact cause of paraneoplastic syndromes is not fully understood, but it is believed that the immune system mistakenly attacks healthy cells in the nervous system, leading to damage and dysfunction. Some research suggests that certain types of cancer may trigger an autoimmune response, while other factors such as genetics or environmental exposures may also play a role.

Paraneoplastic syndromes can be difficult to diagnose, as they often present with symptoms that are similar to those of more common conditions such as multiple sclerosis or stroke. However, certain tests such as electromyography (EMG) and nerve conduction studies (NCS) can help rule out other conditions and confirm the presence of a paraneoplastic syndrome.

Treatment for paraneoplastic syndromes typically focuses on managing symptoms and addressing any underlying cancer that may be present. Medications such as corticosteroids, immunosuppressive drugs, and chemotherapy may be used to reduce inflammation and suppress the immune system, while surgery or radiation therapy may be necessary to remove cancerous tissue. In some cases, plasmapheresis (plasma exchange) may also be recommended to remove harmful antibodies from the blood.

Overall, paraneoplastic syndromes, nervous system are a complex and rare group of disorders that can significantly impact quality of life. Early diagnosis and treatment are key to managing symptoms and improving outcomes for patients with these conditions.

The symptoms of PNP can vary depending on the severity of the nerve damage and the type of cancer present. Common symptoms include:

1. Numbness or tingling sensations in the hands and feet.
2. Weakness and loss of reflexes in the limbs.
3. Pain, burning, or tingling sensations in the limbs.
4. Difficulty with balance and coordination.
5. Muscle wasting and weakness.
6. Decreased sensation to light touch or temperature changes.
7. Abnormal heart rhythms.
8. Fatigue and malaise.

The exact cause of PNP is not fully understood, but it is believed to be an immune-mediated response to the cancer cells. In some cases, PNP may be the first sign of an underlying cancer diagnosis.

There are several diagnostic tests that can help confirm a diagnosis of PNP, including:

1. Electromyography (EMG): This test measures the electrical activity of muscles and can help identify nerve damage.
2. Nerve conduction studies (NCS): This test measures the speed and strength of electrical signals in nerves.
3. Imaging studies (such as CT or MRI scans): These tests can help identify any underlying tumors or other conditions that may be contributing to the PNP symptoms.
4. Blood tests: These can help identify certain antibodies or proteins that are associated with PNP.
5. Biopsy: A biopsy of nerve tissue or a sample of the cancer cells can help confirm the diagnosis of PNP.

Treatment for PNP typically involves managing the underlying cancer and addressing the symptoms of the neuropathy. This may include:

1. Chemotherapy: To treat the cancer and shrink the tumor.
2. Pain management medications: Such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), or anticonvulsants.
3. Physical therapy: To help maintain muscle strength and mobility.
4. Occupational therapy: To assist with daily activities and improve quality of life.
5. Supportive care: Including nutritional support, wound care, and emotional support.

Prognosis for PNP varies depending on the underlying cancer diagnosis and the severity of the neuropathy. However, in general, early detection and treatment can improve outcomes and reduce symptoms. It is important to work closely with a healthcare team to develop an individualized treatment plan and manage any complications associated with PNP.

There are several types of colonic neoplasms, including:

1. Adenomas: These are benign growths that are usually precursors to colorectal cancer.
2. Carcinomas: These are malignant tumors that arise from the epithelial lining of the colon.
3. Sarcomas: These are rare malignant tumors that arise from the connective tissue of the colon.
4. Lymphomas: These are cancers of the immune system that can affect the colon.

Colonic neoplasms can cause a variety of symptoms, including bleeding, abdominal pain, and changes in bowel habits. They are often diagnosed through a combination of medical imaging tests (such as colonoscopy or CT scan) and biopsy. Treatment for colonic neoplasms depends on the type and stage of the tumor, and may include surgery, chemotherapy, and/or radiation therapy.

Overall, colonic neoplasms are a common condition that can have serious consequences if left untreated. It is important for individuals to be aware of their risk factors and to undergo regular screening for colon cancer to help detect and treat any abnormal growths or tumors in the colon.

There are several types of stomach neoplasms, including:

1. Adenocarcinoma: This is the most common type of stomach cancer, accounting for approximately 90% of all cases. It begins in the glandular cells that line the stomach and can spread to other parts of the body.
2. Squamous cell carcinoma: This type of cancer begins in the squamous cells that cover the outer layer of the stomach. It is less common than adenocarcinoma but more likely to be found in the upper part of the stomach.
3. Gastric mixed adenocarcinomasquamous cell carcinoma: This type of cancer is a combination of adenocarcinoma and squamous cell carcinoma.
4. Lymphoma: This is a cancer of the immune system that can occur in the stomach. It is less common than other types of stomach cancer but can be more aggressive.
5. Carcinomas of the stomach: These are malignant tumors that arise from the epithelial cells lining the stomach. They can be subdivided into adenocarcinoma, squamous cell carcinoma, and others.
6. Gastric brunner's gland adenoma: This is a rare type of benign tumor that arises from the Brunner's glands in the stomach.
7. Gastric polyps: These are growths that occur on the lining of the stomach and can be either benign or malignant.

The symptoms of stomach neoplasms vary depending on the location, size, and type of tumor. Common symptoms include abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. Diagnosis is usually made through a combination of endoscopy, imaging studies (such as CT or PET scans), and biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for stomach neoplasms varies depending on the type and stage of the tumor, but early detection and treatment can improve outcomes.

Explanation: Neoplastic cell transformation is a complex process that involves multiple steps and can occur as a result of genetic mutations, environmental factors, or a combination of both. The process typically begins with a series of subtle changes in the DNA of individual cells, which can lead to the loss of normal cellular functions and the acquisition of abnormal growth and reproduction patterns.

Over time, these transformed cells can accumulate further mutations that allow them to survive and proliferate despite adverse conditions. As the transformed cells continue to divide and grow, they can eventually form a tumor, which is a mass of abnormal cells that can invade and damage surrounding tissues.

In some cases, cancer cells can also break away from the primary tumor and travel through the bloodstream or lymphatic system to other parts of the body, where they can establish new tumors. This process, known as metastasis, is a major cause of death in many types of cancer.

It's worth noting that not all transformed cells will become cancerous. Some forms of cellular transformation, such as those that occur during embryonic development or tissue regeneration, are normal and necessary for the proper functioning of the body. However, when these transformations occur in adult tissues, they can be a sign of cancer.

See also: Cancer, Tumor

Word count: 190

White blood cells are an important part of the immune system, and they help to fight off infections and diseases. A low number of white blood cells can make a person more susceptible to infections and other health problems.

There are several different types of leukopenia, including:

* Severe congenital neutropenia: This is a rare genetic disorder that causes a severe decrease in the number of neutrophils, a type of white blood cell.
* Chronic granulomatous disease: This is a genetic disorder that affects the production of white blood cells and can cause recurring infections.
* Autoimmune disorders: These are conditions where the immune system mistakenly attacks its own cells, including white blood cells. Examples include lupus and rheumatoid arthritis.
* Bone marrow failure: This is a condition where the bone marrow does not produce enough white blood cells, red blood cells, or platelets.

Symptoms of leukopenia can include recurring infections, fever, fatigue, and weight loss. Treatment depends on the underlying cause of the condition and may include antibiotics, immunoglobulin replacement therapy, or bone marrow transplantation.

Types of mouth neoplasms include:

1. Oral squamous cell carcinoma (OSCC): This is the most common type of mouth cancer, accounting for about 90% of all cases. It usually occurs on the tongue, lips, or floor of the mouth.
2. Verrucous carcinoma: This type of cancer is slow-growing and typically affects the gums or the outer surface of the tongue.
3. Adenoid cystic carcinoma: This type of cancer is rare and usually affects the salivary glands. It can infiltrate surrounding tissues and cause significant destruction of nearby structures.
4. Mucoepidermoid carcinoma: This type of cancer is relatively rare and occurs most commonly on the tongue or the floor of the mouth. It can be benign or malignant, and its behavior varies depending on the type.
5. Melanotic neuroectodermal tumor: This is a rare type of cancer that affects the melanocytes (pigment-producing cells) in the mouth. It typically occurs in the tongue or the lips.

Symptoms of mouth neoplasms can include:

* A sore or ulcer that does not heal
* A lump or mass in the mouth
* Bleeding or pain in the mouth
* Difficulty swallowing or speaking
* Numbness or tingling in the mouth

Diagnosis of mouth neoplasms typically involves a combination of physical examination, imaging studies (such as X-rays or CT scans), and biopsy. Treatment options vary depending on the type and severity of the cancer, but may include surgery, radiation therapy, chemotherapy, or a combination of these. Early detection and treatment are important for improving outcomes in patients with mouth neoplasms.

Embryonal carcinoma is thought to be caused by genetic mutations that occur during fetal development. These mutations can disrupt the normal growth and development of cells, leading to the formation of abnormal tissue and eventually cancer.

Symptoms of embryonal carcinoma vary depending on the location of the tumor. They may include skin lesions, seizures, developmental delays, and gastrointestinal problems. Diagnosis is typically made through a combination of imaging tests such as ultrasound, CT scans, and MRI scans, as well as biopsy to confirm the presence of cancer cells.

Treatment for embryonal carcinoma usually involves surgery to remove the tumor, as well as chemotherapy and/or radiation therapy to destroy any remaining cancer cells. In some cases, bone marrow or stem cell transplantation may be necessary. Prognosis for this disease is generally poor, as it is often diagnosed at a late stage and can be difficult to treat effectively.

Embryonal carcinoma is different from other types of cancer in that it arises from embryonic tissue rather than adult tissue. It is also characterized by the presence of immature cells, which are not found in more advanced cancers. Overall, embryonal carcinoma is a rare and aggressive form of cancer that requires specialized treatment and management.

Some common effects of chromosomal deletions include:

1. Genetic disorders: Chromosomal deletions can lead to a variety of genetic disorders, such as Down syndrome, which is caused by a deletion of a portion of chromosome 21. Other examples include Prader-Willi syndrome (deletion of chromosome 15), and Williams syndrome (deletion of chromosome 7).
2. Birth defects: Chromosomal deletions can increase the risk of birth defects, such as heart defects, cleft palate, and limb abnormalities.
3. Developmental delays: Children with chromosomal deletions may experience developmental delays, learning disabilities, and intellectual disability.
4. Increased cancer risk: Some chromosomal deletions can increase the risk of developing certain types of cancer, such as chronic myelogenous leukemia (CML) and breast cancer.
5. Reproductive problems: Chromosomal deletions can lead to reproductive problems, such as infertility or recurrent miscarriage.

Chromosomal deletions can be diagnosed through a variety of techniques, including karyotyping (examination of the chromosomes), fluorescence in situ hybridization (FISH), and microarray analysis. Treatment options for chromosomal deletions depend on the specific effects of the deletion and may include medication, surgery, or other forms of therapy.

Pathologic neovascularization can be seen in a variety of conditions, including cancer, diabetic retinopathy, and age-related macular degeneration. In cancer, for example, the formation of new blood vessels can help the tumor grow and spread to other parts of the body. In diabetic retinopathy, the growth of new blood vessels in the retina can cause vision loss and other complications.

There are several different types of pathologic neovascularization, including:

* Angiosarcoma: a type of cancer that arises from the cells lining blood vessels
* Hemangiomas: benign tumors that are composed of blood vessels
* Cavernous malformations: abnormal collections of blood vessels in the brain or other parts of the body
* Pyogenic granulomas: inflammatory lesions that can form in response to trauma or infection.

The diagnosis of pathologic neovascularization is typically made through a combination of physical examination, imaging studies (such as ultrasound, CT scans, or MRI), and biopsy. Treatment options vary depending on the underlying cause of the condition, but may include medications, surgery, or radiation therapy.

In summary, pathologic neovascularization is a process that occurs in response to injury or disease, and it can lead to serious complications. It is important for healthcare professionals to be aware of this condition and its various forms in order to provide appropriate diagnosis and treatment.

The symptoms of limbic encephalitis can vary depending on the severity of the inflammation and the specific areas of the brain affected. Common symptoms include:

* Memory loss and confusion
* Seizures
* Vision problems
* Speech difficulties
* Emotional changes, such as anxiety or depression
* Behavioral changes, such as aggression or apathy
* Personality changes

The exact cause of limbic encephalitis is not fully understood, but it is believed to be an autoimmune response, where the immune system mistakenly attacks healthy tissue in the brain. In some cases, the condition may be triggered by a viral or bacterial infection, and in others, it may be associated with certain medical conditions, such as multiple sclerosis or lupus.

There is no cure for limbic encephalitis, but treatment options are available to manage symptoms and slow the progression of the disease. These may include:

* Medications to reduce inflammation and suppress the immune system
* Anticonvulsants to prevent seizures
* Cognitive rehabilitation to improve memory and other cognitive functions
* Behavioral therapy to manage emotional and behavioral changes

The prognosis for limbic encephalitis varies depending on the severity of the inflammation and the specific areas of the brain affected. In some cases, the condition may resolve on its own over time, while in others, it may result in long-term cognitive and behavioral impairments.

There is currently no way to prevent limbic encephalitis, but early diagnosis and treatment can help manage symptoms and slow the progression of the disease. Researchers are continuing to study the condition to better understand its causes and develop more effective treatments.

Adrenocortical carcinoma can be subdivided into three main types based on their histological features:

1. Typical adrenocortical carcinoma: This is the most common type and accounts for about 70% of all cases. It is characterized by a large, irregular tumor that grows in the cortex of the adrenal gland.
2. Adenomatous adrenocortical carcinoma: This type is less aggressive than typical adrenocortical carcinoma and accounts for about 20% of cases. It is characterized by a small, well-circumscribed tumor that grows in the cortex of the adrenal gland.
3. Adrenocortical sarcoma: This is the least common type and accounts for about 10% of cases. It is characterized by a rare, malignant tumor that grows in the cortex of the adrenal gland.

Adrenocortical carcinoma can cause a variety of symptoms, including abdominal pain, weight loss, fatigue, and skin changes. The diagnosis is typically made through a combination of imaging studies, such as CT scans and MRI, and tissue biopsy. Treatment options include surgery, chemotherapy, and radiation therapy, and the prognosis depends on the stage and aggressiveness of the tumor.

Overall, adrenocortical carcinoma is a rare and aggressive cancer that requires prompt diagnosis and treatment to improve patient outcomes.

Carcinoma verrucous is a type of squamous cell carcinoma that appears as a rough, bumpy, cauliflower-like lesion on the skin or mucous membranes. It is typically found in the oral cavity, lips, tongue, and penis. The tumor grows slowly, and the surface may be covered with a crust or scab that bleeds easily. Carcinoma verrucous tends to occur in older men, particularly those who smoke or drink excessively.

The exact cause of carcinoma verrucous is not known, but it is believed to be linked to exposure to certain viruses, such as human papillomavirus (HPV), and environmental factors, such as smoking and excessive alcohol consumption. The risk of developing carcinoma verrucous may also be increased by chronic inflammation, immunosuppression, and a diet low in fruits and vegetables.

The symptoms of carcinoma verrucous can vary depending on the location of the tumor. In the oral cavity, it may cause painless ulcers or bleeding gums, while in the penis, it may cause difficulty urinating or painful sexual activity. The diagnosis is made by a biopsy, which involves removing a small sample of tissue from the affected area and examining it under a microscope for cancer cells.

Carcinoma verrucous tends to grow slowly, and the prognosis is generally good if the tumor is completely removed before it spreads to other parts of the body. However, local recurrence is common, and the cancer can be difficult to treat once it has spread. The five-year survival rate for carcinoma verrucous is approximately 80%.

Carcinoma verrucous is often treated with surgery, and in some cases, radiation therapy or chemotherapy may also be recommended. Early detection and treatment are important to improve the chances of successful treatment and long-term survival.

A rare type of carcinoma that develops in the gastrointestinal tract (GI tract) such as stomach, small intestine, or large intestine is known as signet ring cell carcinoma. This cancerous tumor is characterized by its appearance under a microscope, which displays cells arranged in a signet ring pattern.

These cells have a distinctive round nucleus and prominent nucleoli that give them a characteristic signet ring appearance. Signet ring cell carcinomas tend to grow slowly, and they do not typically cause any symptoms until they reach an advanced stage.

Signet ring cell carcinoma can be difficult to diagnose because it often looks like other types of noncancerous conditions, such as inflammation or infection. To diagnose this condition, a healthcare provider will need to perform tests such as endoscopy, imaging studies (such as CT scan or MRI), and biopsy.

Treatment options for signet ring cell carcinoma include surgery to remove the tumor, chemotherapy, radiation therapy, or a combination of these. Treatment decisions depend on the stage of the cancer, location, and other factors such as patient's overall health status and personal preferences.

In summary, signet ring cell carcinoma is a rare type of gastrointestinal tract cancer characterized by its distinctive signet ring appearance under a microscope. It tends to grow slowly and can be difficult to diagnose until it reaches an advanced stage. Treatment options include surgery, chemotherapy, radiation therapy, or combination of these depending on the stage of the cancer and other factors.

Sources:
American Cancer Society. (2022). Signet Ring Cell Carcinoma of the Stomach. Retrieved from
National Cancer Institute. (2022). Signet Ring Cell Carcinoma of the Gastrointestinal Tract. Retrieved from

Precancerous changes in the uterine cervix are called dysplasias, and they can be detected by a Pap smear, which is a routine screening test for women. If dysplasia is found, it can be treated with cryotherapy (freezing), laser therapy, or cone biopsy, which removes the affected cells.

Cervical cancer is rare in developed countries where Pap screening is widely available, but it remains a common cancer in developing countries where access to healthcare and screening is limited. The human papillomavirus (HPV) vaccine has been shown to be effective in preventing cervical precancerous changes and cancer.

Cervical cancer can be treated with surgery, radiation therapy, or chemotherapy, depending on the stage and location of the cancer. The prognosis for early-stage cervical cancer is good, but advanced-stage cancer can be difficult to treat and may have a poor prognosis.

The following are some types of uterine cervical neoplasms:

1. Adenocarcinoma in situ (AIS): This is a precancerous condition that occurs when glandular cells on the surface of the cervix become abnormal and grow out of control.
2. Cervical intraepithelial neoplasia (CIN): This is a precancerous condition that occurs when abnormal cells are found on the surface of the cervix. There are several types of CIN, ranging from mild to severe.
3. Squamous cell carcinoma: This is the most common type of cervical cancer and arises from the squamous cells that line the cervix.
4. Adnexal carcinoma: This is a rare type of cervical cancer that arises from the glands or ducts near the cervix.
5. Small cell carcinoma: This is a rare and aggressive type of cervical cancer that grows rapidly and can spread quickly to other parts of the body.
6. Micropapillary uterine carcinoma: This is a rare type of cervical cancer that grows in a finger-like shape and can be difficult to diagnose.
7. Clear cell carcinoma: This is a rare type of cervical cancer that arises from clear cells and can be more aggressive than other types of cervical cancer.
8. Adenocarcinoma: This is a type of cervical cancer that arises from glandular cells and can be less aggressive than squamous cell carcinoma.
9. Sarcoma: This is a rare type of cervical cancer that arises from the connective tissue of the cervix.

The treatment options for uterine cervical neoplasms depend on the stage and location of the cancer, as well as the patient's overall health and preferences. The following are some common treatments for uterine cervical neoplasms:

1. Hysterectomy: This is a surgical procedure to remove the uterus and may be recommended for early-stage cancers or precancerous changes.
2. Cryotherapy: This is a minimally invasive procedure that uses liquid nitrogen to freeze and destroy abnormal cells in the cervix.
3. Laser therapy: This is a minimally invasive procedure that uses a laser to remove or destroy abnormal cells in the cervix.
4. Cone biopsy: This is a surgical procedure to remove a small cone-shaped sample of tissue from the cervix to diagnose and treat early-stage cancers or precancerous changes.
5. Radiation therapy: This is a non-surgical treatment that uses high-energy rays to kill cancer cells and may be recommended for more advanced cancers or when the cancer has spread to other parts of the body.
6. Chemotherapy: This is a non-surgical treatment that uses drugs to kill cancer cells and may be recommended for more advanced cancers or when the cancer has spread to other parts of the body.
7. Immunotherapy: This is a non-surgical treatment that uses drugs to stimulate the immune system to fight cancer cells and may be recommended for more advanced cancers or when other treatments have failed.
8. Targeted therapy: This is a non-surgical treatment that uses drugs to target specific genes or proteins that contribute to cancer growth and development and may be recommended for more advanced cancers or when other treatments have failed.

It is important to note that the choice of treatment will depend on the stage and location of the cancer, as well as the patient's overall health and preferences. Patients should discuss their treatment options with their doctor and develop a personalized plan that is right for them.

Examples of lung diseases, interstitial include:

1. Idiopathic pulmonary fibrosis (IPF): A chronic and progressive disease characterized by inflammation and scarring of the lungs without a known cause.
2. Sarcoidosis: A systemic disease characterized by inflammation and granulomas in various organs, including the lungs.
3. Hypersensitivity pneumonitis (HP): An immune-mediated reaction to inhaled antigens that can lead to inflammation and scarring of the lungs.
4. Pneumoconiosis: A group of lung diseases caused by inhaling dust, including asbestos, silica, and coal dust.
5. Desquamative interstitial pneumonitis (DIP): A rare disease characterized by progressive inflammation and scarring of the lungs.
6. Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD): A rare disease caused by inflammation and scarring of the small airways and surrounding tissue.
7. Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): A sudden worsening of IPF symptoms, often accompanied by inflammation and scarring of the lungs.

Symptoms of lung diseases, interstitial can include:

1. Shortness of breath (dyspnea)
2. Cough
3. Fatigue
4. Chest tightness or pain
5. Dry cough
6. Weight loss
7. Fever

Diagnosis is typically made through a combination of physical examination, medical history, laboratory tests (such as blood tests and lung function tests), and imaging studies (such as chest X-rays and computed tomography (CT) scans).

Treatment options for interstitial lung disease depend on the specific diagnosis and severity of the condition. These may include:

1. Medications to reduce inflammation and prevent further scarring, such as corticosteroids or immunosuppressants.
2. Oxygen therapy to help improve oxygen levels in the blood.
3. Pulmonary rehabilitation to improve lung function and overall health.
4. Surgical procedures, such as lung transplantation, in severe cases where other treatments have failed.
5. Lifestyle changes, such as quitting smoking and avoiding exposure to dust and pollutants.

Some common types of bone neoplasms include:

* Osteochondromas: These are benign tumors that grow on the surface of a bone.
* Giant cell tumors: These are benign tumors that can occur in any bone of the body.
* Chondromyxoid fibromas: These are rare, benign tumors that develop in the cartilage of a bone.
* Ewing's sarcoma: This is a malignant tumor that usually occurs in the long bones of the arms and legs.
* Multiple myeloma: This is a type of cancer that affects the plasma cells in the bone marrow.

Symptoms of bone neoplasms can include pain, swelling, or deformity of the affected bone, as well as weakness or fatigue. Treatment options depend on the type and location of the tumor, as well as the severity of the symptoms. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these.

Examples of precancerous conditions include:

1. Dysplasia: This is a condition where abnormal cells are present in the tissue, but have not yet invaded surrounding tissues. Dysplasia can be found in organs such as the cervix, colon, and breast.
2. Carcinoma in situ (CIS): This is a condition where cancer cells are present in the tissue, but have not yet invaded surrounding tissues. CIS is often found in organs such as the breast, prostate, and cervix.
3. Atypical hyperplasia: This is a condition where abnormal cells are present in the tissue, but they are not yet cancerous. Atypical hyperplasia can be found in organs such as the breast and uterus.
4. Lobular carcinoma in situ (LCIS): This is a condition where cancer cells are present in the milk-producing glands of the breasts, but have not yet invaded surrounding tissues. LCIS is often found in both breasts and can increase the risk of developing breast cancer.
5. Adenomas: These are small growths on the surface of the colon that can become malignant over time if left untreated.
6. Leukoplakia: This is a condition where thick, white patches develop on the tongue or inside the mouth. Leukoplakia can be a precancerous condition and may increase the risk of developing oral cancer.
7. Oral subsquamous carcinoma: This is a type of precancerous lesion that develops in the mouth and can progress to squamous cell carcinoma if left untreated.
8. Cervical intraepithelial neoplasia (CIN): This is a condition where abnormal cells are present on the surface of the cervix, but have not yet invaded surrounding tissues. CIN can progress to cancer over time if left untreated.
9. Vulvar intraepithelial neoplasia (VIN): This is a condition where abnormal cells are present on the vulva, but have not yet invaded surrounding tissues. VIN can progress to cancer over time if left untreated.
10. Penile intraepithelial neoplasia (PIN): This is a condition where abnormal cells are present on the penis, but have not yet invaded surrounding tissues. PIN can progress to cancer over time if left untreated.

It is important to note that not all precancerous conditions will develop into cancer, and some may resolve on their own without treatment. However, it is important to follow up with a healthcare provider to monitor any changes and determine the best course of treatment.

Types of Gallbladder Neoplasms:

1. Adenoma: A benign tumor that grows in the gallbladder wall and can become malignant over time if left untreated.
2. Cholangiocarcinoma: A rare and aggressive malignant tumor that arises in the gallbladder or bile ducts.
3. Gallbladder cancer: A general term used to describe any type of cancer that develops in the gallbladder, including adenocarcinoma, squamous cell carcinoma, and other rare types.

Causes and Risk Factors:

1. Genetics: A family history of gallbladder disease or certain genetic conditions can increase the risk of developing gallbladder neoplasms.
2. Chronic inflammation: Long-standing inflammation in the gallbladder, such as that caused by gallstones or chronic bile duct obstruction, can increase the risk of developing cancer.
3. Obesity: Being overweight or obese may increase the risk of developing gallbladder neoplasms.
4. Age: The risk of developing gallbladder neoplasms increases with age, with most cases occurring in people over the age of 50.

Symptoms and Diagnosis:

1. Abdominal pain: Pain in the upper right abdomen is a common symptom of gallbladder neoplasms.
2. Jaundice: Yellowing of the skin and eyes can occur if the cancer blocks the bile ducts.
3. Weight loss: Unexplained weight loss can be a symptom of some types of gallbladder neoplasms.
4. Fatigue: Feeling tired or weak can be a symptom of some types of gallbladder neoplasms.

Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and PET scans, and a biopsy to confirm the presence of cancer cells.

Treatment:

1. Surgery: Surgery is the primary treatment for gallbladder neoplasms. The type of surgery depends on the stage and location of the cancer.
2. Chemotherapy: Chemotherapy may be used in combination with surgery to treat advanced or aggressive cancers.
3. Radiation therapy: Radiation therapy may be used in combination with surgery to treat advanced or aggressive cancers.
4. Watchful waiting: For early-stage cancers, a wait-and-watch approach may be taken, where the patient is monitored regularly with imaging tests to see if the cancer progresses.

Prognosis:
The prognosis for gallbladder neoplasms depends on the stage and location of the cancer at the time of diagnosis. In general, the earlier the cancer is detected and treated, the better the prognosis. For early-stage cancers, the 5-year survival rate is high, while for advanced cancers, the prognosis is poor.

Complications:

1. Bile duct injury: During surgery, there is a risk of damaging the bile ducts, which can lead to complications such as bile leakage or bleeding.
2. Infection: There is a risk of infection after surgery, which can be serious and may require hospitalization.
3. Pancreatitis: Gallbladder cancer can cause inflammation of the pancreas, leading to pancreatitis.
4. Jaundice: Cancer of the gallbladder can block the bile ducts, leading to jaundice and other complications.
5. Spread of cancer: Gallbladder cancer can spread to other parts of the body, such as the liver or lymph nodes, which can reduce the chances of a cure.

The most common types of laryngeal neoplasms include:

1. Vocal cord nodules and polyps: These are benign growths that develop on the vocal cords due to overuse, misuse, or trauma.
2. Laryngeal papillomatosis: This is a condition where warts grow on the vocal cords, often caused by the human papillomavirus (HPV).
3. Adenoid cystic carcinoma: This is a rare type of cancer that develops in the salivary glands near the larynx.
4. Squamous cell carcinoma: This is the most common type of cancer that develops in the larynx, often due to smoking or heavy alcohol consumption.
5. Verrucous carcinoma: This is a rare type of cancer that develops on the vocal cords and is often associated with chronic inflammation.
6. Lymphoma: This is a type of cancer that affects the immune system, and can develop in the larynx.
7. Melanoma: This is a rare type of cancer that develops from pigment-producing cells called melanocytes.

Symptoms of laryngeal neoplasms can include hoarseness or difficulty speaking, breathing difficulties, and ear pain. Diagnosis is typically made through a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy. Treatment options vary depending on the type and severity of the neoplasm, but may include surgery, radiation therapy, or chemotherapy.

Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.

Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.

Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.

The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.




Symptoms of neutropenia may include recurring infections, fever, fatigue, weight loss, and swollen lymph nodes. The diagnosis is typically made through a blood test that measures the number of neutrophils in the blood.

Treatment options for neutropenia depend on the underlying cause but may include antibiotics, supportive care to manage symptoms, and in severe cases, bone marrow transplantation or granulocyte-colony stimulating factor (G-CSF) therapy to increase neutrophil production.

... lung carcinomas are divided into 8 major taxa: Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma ... combined small cell carcinoma of the lung has been long classified as a subset of small cell carcinoma, and not as a subset of ... small cell lung carcinoma (SCLC), admixed with one (or more) components of any histological variant of non-small cell lung ... December 2007). "Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation". Lung Cancer. ...
... (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which ... 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. ... can also be associated with small cell lung cancer. Unlike extensive-stage small cell lung cancer, limited-stage small cell ... Unlike extensive-stage small cell lung cancer, limited-stage small cell lung cancer is potentially curable. In limited small ...
Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC). It is the second most ... Early squamous-cell carcinoma of the lung (generally as squamous-cell carcinoma in situ) is asymptomatic and may only appear as ... for lung SCC. Lung squamous-cell carcinoma is the second most common histologic type of lung cancer after adenocarcinoma, ... Squamous-cell lung carcinoma share most of the signs and symptoms with other forms of lung cancer. These include worsening ...
It is currently considered to be a subtype of large cell lung carcinoma. LCNEC is often generically grouped among the non-small ... Large cell neuroendocrine carcinoma of the lung (LCNEC) is a highly malignant neoplasm arising from transformed epithelial ... cell lung carcinomas. The World Health Organization classification of lung tumors recognizes a variant of LCNEC, namely " ... Lung Cancer Home Page. The National Cancer Institute site containing further reading and resources about lung cancer. [1]. ...
Small-cell carcinoma Squamous cell carcinoma Adenocarcinoma Large-cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma ... Giant-cell carcinoma of the lung (GCCL) is a rare histological form of large-cell lung carcinoma, a subtype of undifferentiated ... giant-cell carcinoma has the third-worst prognosis among 18 histological forms of lung cancer. (Only small-cell carcinoma and ... of all lung cancers. By the definition of "large-vs.-small-cell carcinoma", the diameter of GCCL cells must be considerably ...
... lung carcinomas are divided into 8 major taxa: Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma ... including mucoepidermoid carcinoma of the lung, adenoid cystic carcinoma of the lung, epithelial-myoepithelial carcinoma of the ... Salivary gland-like carcinomas of the lung generally refers a class of rare cancers that arise from the uncontrolled cell ... Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and ...
Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma ... In the 1960s, small cell lung carcinoma (SCLC) was recognized as a unique form of lung cancer, based both on its appearance ( ... have based patient treatment decisions on a dichotomous division of lung cancers into SCLC and non-small cell lung carcinomas ( ... by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells. Lung cancers have been historically classified ...
... is a type of rare lung tumour under the category of poorly differentiated Non-small-cell lung carcinoma ( ... Moran C, Saul S (2010). "Non Small Cell Carcinomas of the Lung". Tumors and Tumor-like Conditions of the Lung and Pleura. ... spindle cell carcinoma (almost completely consists of spindle cells), pleomorphic carcinoma (at least 10% spindle/giant cells ... it can be classified into giant cell carcinoma (almost completely consists of giant cells), ...
LCC is categorized as a type of NSCLC (non-small-cell lung carcinoma) which originates from epithelial cells of the lung. ... large cell carcinoma of the lung Clear cell carcinoma of the lung Lymphoepithelioma-like carcinoma of the lung Large-cell lung ... LCC is differentiated from small-cell lung carcinoma (SCLC) primarily by the larger size of the anaplastic cells, a higher ... "Histological Typing of Lung Cancer schema" include several variants of LCC, including: Giant-cell carcinoma of the lung ...
Small cell lung carcinoma (SCLC) (FDA Oct 2007). As of 2016, experiments were under way for Neuroblastoma, Brainstem glioma, ... Topotecan is often given in combination with paclitaxel as first line treatment for extensive-stage small-cell lung cancer. ... "FDA Rubber-Stamps APP Pharma's Generic Topotecan for Small Cell Lung and Cervical Cancers". 30 Nov 2010. DNA Topoisomerases and ... In addition, topotecan is experimentally treating Non-small cell lung cancer, Colorectal Cancer, Breast cancer, Non-Hodgkin ...
Syrian hamsters are a model for researching Non-small-cell lung carcinoma, which is one of the types of human lung cancer. In ... "Current role of surgery in small cell lung carcinoma". Journal of Cardiothoracic Surgery. 4 (1): 30. doi:10.1186/1749-8090-4-30 ... Oral squamous-cell carcinoma is a common cancer in humans and difficult to treat. Scientists studying this disease broadly ... The scientist can take cell samples from the mouth of the hamster to measure the development of the cancer. This process has ...
... (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC ... Non-Small Cell Lung Cancer at eMedicine "What Is Non-Small Cell Lung Cancer?". www.cancer.org. Smokers defined as current or ... "Non-Small Cell Lung Cancer Signs and Symptoms". www.cancer.org. Retrieved 4 December 2017. "Non-small cell lung cancer". ... "Non-Small Cell Lung Cancer Treatment". National Cancer Institute. 1 January 1980. Retrieved 4 December 2017. "Non-small cell ...
"Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other ... Another reason is that lung cancer, particularly small cell lung cancer, is very aggressive with very low five-year survival ... is cell cycle-independent. TK1 is synthesized by the cell during the S phase of cell division. After cell division is completed ... "Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis". Cancer. 66 (4): 722- ...
Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene. 2007 Feb;26(7):1046. Dierks C, Beigi R, ... Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003 Mar;422(6929):313. Yuan Z ... Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell ... small cell lung cancer, pancreatic cancer, intracranial meningioma, recurrent glioblastoma, and acute myeloid leukemia. ...
It was counterproductive in non-squamous non-small-cell lung carcinoma. International Nonproprietary Names for Pharmaceutical ... name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma ... Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28. " ...
... small-cell lung cancer, ovarian cancer). It has been granted Orphan drug status for Merkel cell carcinoma. It has reported ... "ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung ... encouraging Phase II results for small-cell lung cancer. Dimond PF (9 March 2010). "Antibody-Drug Conjugates Stage a Comeback ... It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a ...
Celiac disease Ulcerative colitis Crohn's disease Hepatic cirrhosis Hepatocellular carcinoma Lung cancer, including small cell ... Mignogna MD, Fortuna G, Satriano AR (December 2008). "Small-cell lung cancer and necrolytic migratory erythema". The New ... Wilkinson DS (1973). "Necrolytic migratory erythema with carcinoma of the pancreas". Transactions of the St. John's Hospital ... swollen epidermal cells and necrosis of the superficial epidermis are most characteristic. Immunofluorescence is usually ...
Increased expression of mir-126 inhibits cell proliferation of non-small cell lung carcinoma cells in vitro and prevents tumour ... "MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines". Biochem Biophys Res Commun. 373 (4): 607-12. doi: ... Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L (2010). "miR-126 inhibits non-small cell lung cancer cells proliferation by ... This includes controlled cell death and responses to wounds. During apoptosis cell death, cells release apoptotic bodies ...
"Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies". Lancet. 341 (8836): 21-22. doi: ... which are cell-cell adhesion molecules found in desmosomes). Underlying cancer or irreversible system impairment, seen in acute ... Unlike a mass effect, it is not due to the local presence of cancer cells. Paraneoplastic syndromes are typical among middle- ... In this scenario, the body may produce antibodies to fight off the tumor by directly binding and destroying the tumor cell. ...
... -containing drugs Gefitinib for treatment of non-small-cell lung carcinoma. Lapatinib for treatment of advanced- ... "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to ... Lapatinib eliminates the growth of breast cancer stem cells that cause tumor growth. The binding of lapatinib to the ATP- ... the cancer stem cell. Archived from the original on 2008-11-26. Nelson MH, Dolder CR (February 2006). "Lapatinib: a novel dual ...
Possible applications include non-small-cell lung carcinoma, hepatocellular carcinoma, and oesophageal cancer. In 2017, it was ... Tivantinib (ARQ197; by Arqule, Inc.) is an experimental small molecule anti-cancer drug. It is a bisindolylmaleimide that binds ... "ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko ... announced that a phase III clinical trial for advanced hepatocellular carcinoma had failed to meet the primary endpoint. " ...
Trueman was diagnosed with small cell carcinoma of the lung in May 2006. He died of the disease on 1 July 2006 at Airedale ... This award was discontinued in 2004, two years before Trueman was diagnosed with lung cancer, because its organisers feared it ... Deaths from lung cancer, Derbyshire cricketers, England Test cricketers, English cricket commentators, English cricketers of ...
In lung carcinoma, fibronectin expression is increased especially in non-small cell lung carcinoma. The adhesion of lung ... ISBN 978-0-387-97050-9. Han S, Khuri FR, Roman J (January 2006). "Fibronectin stimulates non-small cell lung carcinoma cell ... The RGD sequence (Arg-Gly-Asp) is located in III10 and is the site of cell attachment via α5β1 and αVβ3 integrins on the cell ... "Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma". Cancer Biology & Therapy ...
... and non-small-cell lung carcinoma, which can be addicted to the gene EGFR. Oncogene addiction can be treated by using enzyme ... As a result, cancer cells rely on continuous signaling from these oncogenes for their survival. The term was coined in 2002 by ... Tulpule, Asmin; Bivona, Trever G. (2020). "Acquired Resistance in Lung Cancer". Annual Review of Cancer Biology. 4: 279-297. ... Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells". Biomarkers in Cancer. 7s2 (Suppl 2): 25-32. doi:10.4137/BIC.S29326 ...
In adults, most cases are associated with breast carcinoma or small-cell lung carcinoma. It is one of the few paraneoplastic ( ... and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes". Neurology. 62 (9): 1526-32. doi: ... possibly by expanding the memory B cell population. Studies have generally asserted that 70-80% of children with OMS will have ...
Shtivelman E (Jun 1997). "A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma". Oncogene ... Cell. Biol. 20 (2): 583-93. doi:10.1128/MCB.20.2.583-593.2000. PMC 85138. PMID 10611237. Xiao H, Palhan V, Yang Y, Roeder RG ( ... Cell. Biol. 24 (16): 7091-101. doi:10.1128/MCB.24.16.7091-7101.2004. PMC 479715. PMID 15282309. Suzuki Y, Yamashita R, Shirota ... NicAmhlaoibh R, Shtivelman E (2001). "Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro". ...
Middle mediastinum: lymphadenopathy, metastatic disease such as from small cell carcinoma from the lung. Posterior mediastinum ... It is surrounded by the chest wall in front, the lungs to the sides and the spine at the back. It extends from the sternum in ... It contains all the organs of the thorax except the lungs. It is continuous with the loose connective tissue of the neck. The ... Chandra S, Laor YG (April 1975). "Lung scan and wide mediastinum". J. Nucl. Med. 16 (4): 324-5. PMID 1113190. von Kodolitsch Y ...
In contrast, non-small cell lung carcinomas (NSCLC's) are more likely to remain localized to the thorax during development, and ... Most small cell lung carcinomas (SCLC's) metastasize to distant organs early on in their course, rendering surgery ineffective ... While there have been no randomized clinical trials of targeted agents in combined small-cell lung carcinoma (c-SCLC),[citation ... Dempke WC, Suto T, Reck M (March 2010). "Targeted therapies for non-small cell lung cancer". Lung Cancer (Amsterdam, ...
Lemmo, W; Tan, G (2016). "Prolonged Survival After Dichloroacetate Treatment of Non-Small-Cell Lung Carcinoma-Related ... cell death) of the malignant cells. In vitro work with DCA on neuroblastomas (which have fewer recognised mitochondrial ... These effects were not observed in non-tumor cells. Neuropathy has been a problem in some clinical trials with DCA causing them ... It can kill normal cells as well. A randomized controlled trial in children with congenital lactic acidosis found that while ...
He died of small cell lung carcinoma in Yerevan prison on October 8, 1940. "Sahak Torosyan - Wikipedia, the free encyclopedia ...
Cell Dev. Biol. 17 (5): 544-54. doi:10.1016/j.semcdb.2006.09.001. PMID 17071117. Minghetti L, Pocchiari M (2007). " ... Saba N, Jain S, Khuri F (2004). "Chemoprevention in lung cancer". Curr Probl Cancer. 28 (5): 287-306. doi:10.1016/j. ... small amounts of oxidation products are formed due to the oxygen trapping of an allylic radical intermediate at positions 13 ... "A new cyclo-oxygenase-2 gene variant in the Han Chinese population is associated with an increased risk of gastric carcinoma". ...
... carcinoma Small cell carcinoma Neuroendocrine tumour Glassy cell carcinoma Villoglandular adenocarcinoma Though squamous cell ... In advanced disease, metastases may be present in the abdomen, lungs, or elsewhere. Symptoms of advanced cervical cancer may ... About 90% of cervical cancer cases are squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. ... Histologic subtypes of invasive cervical carcinoma include: Squamous cell carcinoma (about 80-85%) adenocarcinoma (about 15% of ...
... radial arrangements of neoplastic cells around small blood vessel) and nuclear palisading (i.e. parallel arrangements of the ... 1 to lung and 1 to bone. By the end of the study, 47 individuals had no evidence of disease and 2 had died of unknown causes. ... These cells, which are not myoepithelial cells, have been termed globoid cells. They have eosinophilic cytoplasm (i.e. pink or ... Rarely, invasive SPC occurs with nearby invasive carcinoma of NST, lobular carcinoma, cribriform carcinoma, or tubular ...
... non-small-cell lung carcinoma, renal cell carcinoma, and breast cancer. The forced over expression of CMTM5-v1 in Huh7 human ... "Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer". International ... Cai B, Xiao Y, Li Y, Zheng S (August 2017). "CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and ... hepatic cells also inhibited the ability of these cells to grow in a mouse model of cancer. Finally, various cancer human cell ...
RIG-G has shown the capacity to inhibit NF-κB and STAT3 signaling in lung cancer cells, which demonstrates the potential of ... Control of chronic hepatitis C by IFN is associated with reduced hepatocellular carcinoma. Unconfirmed results suggested that ... clinical trials and the preparation of small amounts of interferon messenger RNA to clone the human alpha and beta interferon ... A virus-infected cell releases viral particles that can infect nearby cells. However, the infected cell can protect neighboring ...
Pulmonary Typical bronchial carcinoid Atypical bronchial carcinoid Large cell neuroendocrine carcinoma Small cell lung cancer ... tumors Non-functioning endocrine pancreatic tumors Insulinoma Gastrinoma Glucagonoma VIPoma Adrenals Adrenocortical carcinoma ...
... in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/ ... the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumors express PD-L1 with a ≥ 50% ... In October 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) in people ... In March 2021, the accelerated approval indication in the US for the treatment of people with metastatic small cell lung cancer ...
... such as lung cancer, breast cancer, and hepatocellular carcinoma. HAVCR2/ galectin-9 interaction attenuated T-cell expansion ... "Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer". Biochemical and ... Moreover, galectin-9 contributed to tumorigenesis by tumor cell transformation, cell-cycle regulation, angiogenesis, and cell ... "Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines". International Journal of ...
... most cells looked fairly normal and there was no evidence of mitosis which would indicate that cells were rapidly dividing), ... This will result in compression of organs and will destroy the function of the colon, small intestine, stomach, or other organs ... While the majority of these cases are associated with appendiceal carcinomas, other conditions may also be found, including ... lung, breast, fallopian tubes, and the pancreas. This disease is often discovered during surgery for other conditions, e.g., ...
Several cell types or tissues, e.g. osteoblasts, chondrocytes, cardiac tissue, gastrointestinal smooth muscle cells, and ... There Is too little experience on the treatment of LECT2 amyloidosis (ALECT2) to establish recommendations. There is no ... They may have histological evidence of LECT2 amyloid deposition in the liver, lung, spleen, kidney, and adrenal glands of ... of individuals with Hepatocellular carcinoma. In the latter form of liver cancer, LECT2 levels increase with increasingly poor ...
... , sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC ... It has received regulatory approval for use as a treatment for non-small cell lung cancer, although there is emerging evidence ... Vavalà T (2017). "Role of afatinib in the treatment of advanced lung squamous cell carcinoma". Clinical Pharmacology. 9: 147- ... May 2012). "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of ...
The small intestine consists of the duodenum, jejunum and ileum. Inflammation of the small intestine is called enteritis, which ... Liang, Qiaoyi; Yao, Xiaotian; Tang, Senwei; Zhang, Jingwan; Yau, Tung On; Li, Xiaoxing; Tang, Ceen-Ming; Kang, Wei; Lung, ... Congenital disorders of the stomach include pernicious anaemia, in which a targeted immune response against parietal cells ... "Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments". World Journal of ...
... knockout mice display serious central nervous system and lung defects have small lungs, undescended testes, and a hopping gait ... signaling and they are implicated as potent oncogenes in the embryonal carcinoma cell. The protein encoded by this gene ... "Expression of the GLI2 oncogene and its isoforms in human basal cell carcinoma". The British Journal of Dermatology. 148 (5): ... resembling those of basal cell carcinoma (BCC). Unlike Gli1 transgenic mice, Gli2 transgenic mice only developed BCC-like ...
... all-trans retinoic acid dependent expression of HOXB and HOXC homeogenes in human embryonal and small-cell lung carcinoma cell ... Scott MP (November 1992). "Vertebrate homeobox gene nomenclature". Cell. 71 (4): 551-3. doi:10.1016/0092-8674(92)90588-4. PMID ...
A statistically significant subset of these early miners later developed small cell carcinoma after exposure to uranium ore. ... Gottlieb, LS; LA Husen (1982-04-01). "Lung cancer among Navajo uranium miners". Chest. 81 (4): 449-452. doi:10.1378/chest.81.4. ...
"Marijuana use and increased risk of squamous cell carcinoma of the head and neck". Cancer Epidemiology, Biomarkers & Prevention ... "The impact of cannabis on your lung". British Lung Association. June 2012. Archived from the original on 27 September 2013. ... Studies on cannabis and memory are hindered by small sample sizes, confounding drug use, and other factors. The strongest ... A study by the British Lung Foundation published in 2012 identifies cannabis smoke as a carcinogen and also finds awareness of ...
... mammary gland tumors and endometrial carcinomas in females, and C-cell adenomas/adenocarcinomas of the thyroid gland and tumors ... The rat found early use in laboratory research in five areas: W. S. Small suggested that the rate of learning could be measured ... Hsu CC, Lai SC (December 2007). "Matrix metalloproteinase-2, -9 and -13 are involved in fibronectin degradation of rat lung ... and gain weight from an increase in both the size and number of fat cells. Obesity in Zucker rats is primarily linked to their ...
It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given ... Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by ...
... squamous-cell carcinomas (head-and-neck cancers, some lung cancers), etc. The epothilones, e.g. Ixabepilone, work in a similar ... Ren XD, Kiosses WB, Schwartz MA (February 1999). "Regulation of the small GTP-binding protein Rho by cell adhesion and the ... Some cell types, such as plant cells, do not contain well defined MTOCs. In these cells, microtubules are nucleated from ... This interference with microtubule dynamics can have the effect of stopping a cell's cell cycle and can lead to programmed cell ...
This may be done by an open incision in the abdomen (laparotomy) or through a few smaller incisions with the help of cameras ( ... Although 70-90 percent of people with appendicitis may have an elevated white blood cell (WBC) count, there are many other ... Cunha BA, Pherez FM, Durie N (July 2010). "Swine influenza (H1N1) and acute appendicitis". Heart & Lung. 39 (6): 544-6. doi: ... Arnbjörnsson E (May 1982). "Acute appendicitis as a sign of a colorectal carcinoma". Journal of Surgical Oncology. 20 (1): 17- ...
... and lung cancers, which led to its use as a prognostic marker for these cancers. Elevated Hsp70 levels in tumor cells may ... Lamian V, Small GM, Feldherr CM (Oct 1996). "Evidence for the existence of a novel mechanism for the nuclear import of Hsc70". ... In particular, overexpression of HSP72 has been linked to the development some cancers, such as hepatocellular carcinoma, ... Cell. 122 (6): 957-68. doi:10.1016/j.cell.2005.08.029. hdl:11858/00-001M-0000-0010-8592-0. PMID 16169070. S2CID 8235923. Imai Y ...
Small cell carcinoma is a rare (1%) type that cannot be diagnosed using PSA. As of 2009[update] researchers were investigating ... Further investigation with this substance revealed that it could interfere with the LT receptors in the lung carcinoma [38]. In ... LNCaP cells express AR, but PC-3 and DU-145 cells express very little or no AR. The proliferation of LNCaP cells is androgen- ... Initially, small clumps of cancer cells remain within otherwise normal prostate glands, a condition known as carcinoma in situ ...
"Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after ... "MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells". Asian Pacific Journal of Cancer Prevention. 12 ... Xing L, Todd NW, Yu L, Fang H, Jiang F (August 2010). "Early detection of squamous cell lung cancer in sputum by a panel of ... High miR-708 expression levels are observed in lung cancers due to their oncogenic role in lung cancer tumour growth and ...
High-grade pulmonary neuroendocrine tumor Small cell lung cancer (SCLC) Large cell neuroendocrine carcinoma (LCNEC of the lung ... and pulmonary small cell carcinoma (SCLC), with significant clinical, epidemiologic and genetic differences. Pulmonary ... Both LCNEC and SCLC can demonstrate histologic heterogeneity with other major histologic types of lung carcinoma, such as ... When neuroendocrine cell hyperplasia and tumorlets are extensive, they represent the rare preinvasive lesion for carcinoids ...
One study compared the enzymes of liver metastases of giant-cell lung carcinoma and nonmalignant placental cells. The two were ... the enzyme is in solution with a smaller amount of proteins than there are in another portion of the cell. The proteins' heat ... embryonic stem cells or embryonal carcinoma cells). There is a positive correlation between serum bone alkaline phosphatase ... "Appendix E: Stem Cell Markers". Stem Cell Information. National Institutes of Health, U.S. Department of Health and Human ...
... aldolase a is a potential metastasis-associated marker of lung squamous cell carcinoma and promotes lung cell tumorigenesis and ... "The changes in aldolase isoenzyme pattern during development of the human kidney and small intestine--demonstrated in organ ... including lung squamous cell carcinoma (LSCC), renal cancer, and hepatocellular carcinoma. It is proposed that ALDOA ... "Histological examination of the aldolase monomer composition of cells from human kidney and hypernephroid carcinoma". Beiträge ...
4TO7 cells). Overexpression of miR-200c in non-metastatic 4TO7 cells readily enables MET and colonization of the liver and lung ... DNA methylation of the mir-200c/mir-141 promoter occurs aberrantly in certain aggressive carcinoma cells that are of epithelial ... Dykxhoorn DM (2010). "MicroRNAs and metastasis: little RNAs go a long way". Cancer Res. 70 (16): 6401-6406. doi:10.1158/0008- ... the miR-200 family is highly expressed only in the cells that are able to form metastases (4T1 cells) but not in other cells ...
It is known to be a major risk factor for cancers (squamous cell carcinoma) of the mouth and esophagus. As with chewing tobacco ... Pan masala with a small quantity of tobacco is called gutka. The easily discarded, small plastic supari or gutka pouches are a ... Systemic effects of areca nut Areca nut affects almost all organs of the human body, including the brain, heart, lungs, ... pre-cancerous oral lesions and squamous cell carcinoma. Acute effects of betel chewing include asthma exacerbation, ...
Numb loss has also been demonstrated in Non-small-cell lung carcinoma, salivary gland carcinoma, and chronic myelogenous ... The pIIa cell divides to produce a bristle cell and a socket cell, while the pIIb cell divides to produce a neuron and a glial ... The other daughter cell becomes a progenitor cell to fill the lost role of the parent cell and maintain proliferation. In ... The posterior daughter cell is called the pIIa cell and the anterior daughter cell is called the pIIb. ...
Cytopathology reveals clusters of cells with uniform round nuclei. These cells do not have many of the features usually ... Smaller tumors are undetectable without a rectal examination, while larger tumors can cause pain and straining to defecate. ... Anal Sac Tumors in Cats and Dogs from Pet Cancer Center Anal sac gland carcinoma: veterinary factsheet from Davies Veterinary ... and eventually lungs and, less commonly, bones. The sublumbar (iliac) lymph nodes are the most common site of metastasis and ...
... however most of non-small cell lung cancer tumours are not sensitive to this treatment. As an alternative to chemoterapy, ... Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, ... Point-of-care blood device for fast and reliable prediction of drug response in non- small-cell lung carcinoma patients from ... Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, however most of non- ...
X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma ... X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma ... Bisulfite sequencing PCR (BSP) was used to evaluate the methylation status of lung cancer cells with or without X-ray treatment ... X-ray treatment significantly inhibits proliferation and invasion of lung cancer cells with hypermethylation of the Dab2 gene ...
This survey aims to understand the current UK practice for non-small cell lung carcinoma (NSCLC) and identify barriers that may ... management; non-small cell lung carcinoma; oncogenic genetic testing; real world practice; treatment ... Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK ... Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional ...
Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. 05 February 2020 ... We excluded patients with microsatellite unstable tumours, because these are a small subset of sporadic CRCs with different ... Integrated whole transcriptome and small RNA analysis revealed multiple regulatory networks in colorectal cancer. 14 July 2021 ... earlier studies have reported that c-Myc has conflicting apoptosis-induction and cell proliferation roles in normal and tumour ...
Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. ... A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC). The safety and ... This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung ... Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung ...
These include colon adenocarcinoma, esophageal carcinoma, gastric carcinoma, non-small cell lung cancer, thoracic scleroderma, ... Because of the paucity of air progressing through the hypertensive LES, the gastric air bubble may be small or absent. [24] ... Primary achalasia is the most common subtype and is associated with loss of ganglion cells in the esophageal myenteric plexus. ... According to Gockel and colleagues, pseudoachalasia, caused by carcinomas or other disease processes or by iatrogenic ...
Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. ... Non-small Cell Lung Cancer (NSCLC) Drug: Atezolizumab Drug: Tiragolumab Drug: Durvalumab Phase 3 ... Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03). The safety and scientific validity of this study is ... unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based ...
STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world-data..docx ... lung cancernon-small cell lung cancer (NSCLC)thymidineOncology and Carcinogenesis not elsewhere classified ... Supplementary Data: STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world- ... STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world-data. ...
Lung Neoplasms* / drug therapy * Neutropenia / epidemiology * Small Cell Lung Carcinoma* / drug therapy ... Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung ... Keywords: Clinical utility index; Exposure-response; Lurbinectedin; Pharmacokinetics; Small-cell lung cancer. ...
Common symptoms of lung cancer include: constant chest pain and coughing blood. Read more. ... Lung cancer is one of the most common cancers in the world. ... ClinicalTrials.gov: Carcinoma, Non-Small-Cell Lung (National ... small cell lung cancer and non-small cell lung cancer. These two types grow differently and are treated differently. Non-small ... Non-Small Cell Lung Cancer) (National Cancer Institute) Also in Spanish * Treatment Option Overview (Small Cell Lung Cancer) ( ...
lung non-small cell carcinoma. IDs. lung non-small cell carcinoma DOID:3908. EFO:0003060. KEGG:05223. MESH:D002289. NCI:C2926. ... Click on grid cells to view annotations.. *Blue cells = expressed in wild-type.. Gray triangles = other expression annotations ... hepatocellular carcinoma DOID:684. DOID:5005. EFO:0000182. ICD10CM:C22.0. MESH:D006528. NCI:C3099. OMIM:114550. ORDO:88673. ... Lung tumors and metastases of B16 melanoma do not occur in null mutant mice, suggesting inability to support tumor invasiveness ...
Incorrect: The histology was small-cell carcinoma of the lung.. Correct: The histologic diagnosis was small-cell carcinoma of ... Morphology is not a synonym for shape, and such statements as "The cell showed a flat morphology" are wrong. In this example, ... For the term "large T-antigen," use a capital letter "T"; for the term "small t-antigen," use a lowercase letter "t." ... The procedure of removing and examining tissue, cells, or fluids from the living body. Observations are made on the biopsy ...
Carcinoma, Non-Small-Cell Lung. *Mesothelioma. Anatomical therapeutic chemical (ATC) code L01BA04 ... advanced non-small-cell lung cancer of the kind known as non-squamous, where it is used either in combination with cisplatin ... Non-small cell lung cancer. Ciambra in combination with cisplatin is indicated for the first line treatment of patients with ... Ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer ...
... in the treatment of small cell lung cancer. ... Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma b: ... Weve seen tremendous advances in non-small cell lung cancer. And I feel like were just getting started with small cell lung ... Welcome to Season 2 of Medscapes InDiscussion Series on Lung Cancer. Today well be discussing small cell lung cancer, and Id ... Weiss: What I find most exciting about this subtyping is that it shows us four types of small cell lung cancer that have very ...
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck quantity ... Non-Small Cell Lung Cancer - Adjuvant Therapy for Completely Resected Stages I-IIIA quantity ... Stage IV Non-Small Cell Lung Cancer without Driver Alterations American Society of Clinical OncologyCancer Care Ontario ... Non-Small Cell Lung Cancer - Adjuvant Therapy for Completely Resected Stages I-IIIA. American Society of Clinical Oncology ...
Lung cancer can be caused by many risk factors other than smoking cigarettes. ... Adenocarcinomas and squamous cell carcinomas are two types of non-small cell lung cancer. A few (6% to 8%) are small cell lung ... are squamous cell carcinomas (cancer that forms in the thin, flat cells lining the inside of the lungs). ... cancer that begins in the cells that line the lungs tiny air sacs and make substances such as mucus). About 10% to 20% ...
The challenge for oncologists treating patients with stage III non-small-cell lung cancer (NSCLC) is to optimize a treatment ... Kupelian PA, Komaki R, Allen P: Prognostic factors in the treatment of node-negative non-small-cell lung carcinoma with ... Non-Small-Cell Lung Cancer Collaborative Group: Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated ... Altered Fractionation RT for Locally Advanced Non-Small-Cell Lung Cancer. The realization that local control of lung cancer ...
The FDA approved Keytruda for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma ... Your search for non small cell lung cancer returned 19 results Active Filters. Click on a filter below to refine your search. ... Keytruda Approved to Treat Metastatic Small Cell Lung Cancer The approval was based on data from 83 patients with SCLC who were ... Your search for non small cell lung cancer returned 19 results Sort Results: Relevant Recent ...
Doctors classify the stages of non-small cell lung cancer and small cell lung cancer differently. Learn more about how they are ... Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two most common types. ... Squamous cell carcinoma in situ: When abnormal cells are detected in the tissues that line the respiratory tract. These cells ... Learn about the five-year survival rates for non-small cell lung cancer and for small-cell lung cancer. ...
... renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), ... Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping ... IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples ... IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum ...
The small-molecule KIT inhibitor suntinib is approved as a treatment for renal cell carcinoma, as a second-line medication for ... Mutations of the gene are associated with lung adenocarcinoma, colorectal carcinoma, mucinous adenoma, and ductal carcinoma of ... non-small cell lung cancer; ER, estrogen receptor; PgR, progesterone receptor; FDP, fibrin degradation protein; HE4, human ... tiny.cc/pa0i3, tiny.cc/6wjgg. EGFR. Protein Emerges as Target, Particularly in Lung Cancer. Epidermal growth factor receptor, ...
Extensive Stage Small Cell Lung Carcinoma. * Head and Neck Carcinoma. * HER2/Neu Negative ... Non-small cell lung cancer stage IIIA, IIIB, IV. - Small cell lung cancer, limited stage and extensive stage. - Castration- ... Renal cell carcinoma, stage IV. - Breast cancer, stage IV, if triple negative ER/PR/H2N negative or on systemic. chemotherapy. ... Triple-Negative Breast Carcinoma. ELIGIBILITY Inclusion Criteria:. - Newly diagnosed patients for the following conditions. - ...
Pathologic Findings in Small Cell Bladder Carcinoma * 2001/viewarticle/992689. Genes Dont Explain Worse Prostate Cancer ... 2001https://www.medscape.com/etumor/lung-cancer-s01/e06. NSCLC e-Tumor Boards: Case 6: NSCLC with Multiple Primaries ... No driver mutations were seen in a high proportion of patients with chromophobe renal cell carcinoma and pancreatic ... Driver point mutations played a major role in colorectal adenocarcinomas and mature B-cell lymphomas. Many driver mutations ...
Nivolumab for Small Cell Lung Cancer. Closing out 2020, Bristol Myers Squibb announced their decision to withdraw the ... Durvalumab for Urothelial Carcinoma. On February 22, 2021, AstraZeneca decided to withdraw the indication for durvalumab ( ... Pembrolizumab for Small Cell Lung Cancer. On March 1, 2021, Merck voluntarily withdrew the US indication for pembrolizumab ( ... for the treatment of patients with small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy ...
Publications] Emiko Morimoto: Adenovirus-Mediated Suicide Gene Transfer to Small Cell Lung Carcinoma Using a Tumor-specific ... Use of Gastrin-Releasing Peptide Promoter for Specific Expression of Thymidine Kinase Gene in Small-Cell Lung Carcinoma ... Publications] Michiko Tanaka: Neuiron Specific Enlolase Promoter for Suicide Gene Therapy in Small Cell Lung ... Between Apoptosis and Immunohistochemical Staing for Proliferating Cell Nuclear Antiaen and Ki-67 in Non-small Cell Lung ...
Lung (Carcinoma; Non small cell carcinoma). View this tissue/histology in the Cancer Browser Screening method. Whole exome ... cell-line. Curated features. Sample details. n/a Tumour details. n/a Individual details. Ethnicity. Caucasian. Normal tissue ... Only available in the cell lines site. Non-mutant genes. This tab shows the genes with no mutations in this sample. You can ... COSMIC, Cell Lines, CMC, COSMIC-3D v98 and Actionability v9 are now available 🎉 ...
Neoplasms, Medical Oncology, Oncology Service, Hospital, Lung, Lung Neoplasms, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell ... Lung, Radiotherapy, Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, Precancerous Conditions, Genes, ... Carcinoma, Small Cell 1 * Carcinoma, Non-Small-Cell Lung 1 * Antineoplastic Protocols 1 ...
Non Small Cell Lung Cancer (36). Renal Cell Carcinoma (36). Toxicities (36). ... Case Studies in Immunotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma - SITC CPG Webinar: Recording and ... Immunotherapy for the Treatment of Hepatocellular Carcinoma - SITC CPG Recorded Webinar and Presentation Slides On November 8, ... Practical Management Pearls for Immunotherapy for the Treatment of Lung Cancer and Mesothelioma - SITC CPG Webinar Recording ...
Squamous cell carcinoma may predominate in a small percentage of rodent tumors, but has rarely been observed to occur de novo. ... cells in culture, and lung tissue in vivo. A primary step in response to asbestos fiber challenge to a number of cell types is ... c-fos and c-jun proto-oncogenes in target cells of the lung and pleura by carcinogenic fibers. Am. J. Respiratory Cell and ... phagocytized by a number of cell types in the lung including epithelial cells (Churg et al., 2000). Once within a phagolysosome ...
... small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of all lung cancers. ... Lung cancers are generally divided into two main categories: ... is used for all lung carcinomas except small-cell lung cancer. ... Lung cancers are generally divided into two main categories: small cell lung cancer (SCLC) and non-small cell lung cancer ( ... Non-small cell lung cancer. Left pleural effusion and volume loss secondary to non-small cell carcinoma of the left lower lobe ...
  • Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, however most of non-small cell lung cancer tumours are not sensitive to this treatment. (europa.eu)
  • This survey aims to understand the current UK practice for non-small cell lung carcinoma (NSCLC) and identify barriers that may impact patient treatment and outcomes. (bvsalud.org)
  • This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC). (clinicaltrials.gov)
  • The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression. (clinicaltrials.gov)
  • The challenge for oncologists treating patients with stage III non-small-cell lung cancer (NSCLC) is to optimize a treatment strategy using nonsurgical therapies. (cancernetwork.com)
  • The term locally advanced non-small-cell lung cancer (NSCLC) is used to describe disease that is too extensive for primary surgical resection, is limited to the thorax, and, technically, allows inclusion of the entire tumor within a reasonable radiation field. (cancernetwork.com)
  • Patients with NSCLC were expected to comprise 25% to 40% of the 178,100 new lung cancer patients diagnosed in 1997 in the United States. (cancernetwork.com)
  • In patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), treatment with osimertinib and gefitinib plus pemetrexed-based chemotherapy was found to be superior to other first-line therapies, according to a systematic review and network meta-analysis published in the BMJ. (empr.com)
  • In patients with naïve advanced non-small cell lung cancer (NSCLC) and high PD-LI expression who are treated with pembrolizumab, the use of intravenous (IV) antibiotics may negatively impact progression free survival (PFS) and overall survival, according to research presented at the IASLC 2019 World Conference on Lung Cancer. (empr.com)
  • Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two most common types. (cancercenter.com)
  • NSCLC is the more common of the two, accounting for 80 to 85 percent of all lung cancers, according to the American Cancer Society (ACS). (cancercenter.com)
  • Doctors frequently classify the stages of NSCLC and SCLC using the TNM system, which involves the use of letters to denote lung tumor characteristics. (cancercenter.com)
  • Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. (medscape.com)
  • Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. (medscape.com)
  • Because most lung cancers cannot be cured with currently available therapeutic modalities, the appropriate application of skilled palliative care is an important part of the treatment of patients with NSCLC. (medscape.com)
  • There is an increasing need to subtype non-small cell lung carcinoma (NSCLC) into squamous cell carcinoma and adenocarcinoma of lung, and this subtyping guides the treatment with the advent of targeted therapies that are available for cases of adenocarcinoma of lung, by which prognosis can be improved. (who.int)
  • Aims and Objectives This study was carried out to check the expression of p63 and TTF-1 in diagnostically difficult cases, such as NSCLC, poorly differentiated lung carcinomas on pulmonary cytology samples, and to further subtype them into squamous cell and adenocarcinoma. (who.int)
  • Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib. (empr.com)
  • On February 22, 2021, AstraZeneca decided to withdraw the indication for durvalumab (Imfinzi) in the United States (US) for the treatment of locally advanced or metastatic urothelial carcinoma in previously treated adults, following a meeting with the FDA. (clinicaladvisor.com)
  • Genetic alterations responsible for metastatic phenotypes of lung cancer cells. (genome.jp)
  • KEYTRUDA has shown meaningful efficacy in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by surgery or radiation," said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. (merck.com)
  • In the United States, about 10% to 20% of lung cancers, or 20,000 to 40,000 lung cancers each year, happen in people who never smoked or smoked fewer than 100 cigarettes in their lifetime. (cdc.gov)
  • Researchers estimate that secondhand smoke contributes to about 7,300 and radon to about 2,900 of these lung cancers. (cdc.gov)
  • About 50% to 60% of lung cancers found in people who never smoked are adenocarcinomas (cancer that begins in the cells that line the lung's tiny air sacs and make substances such as mucus). (cdc.gov)
  • A few (6% to 8%) are small cell lung cancers, and the rest are other types of lung cancer. (cdc.gov)
  • Unlike trastuzumab, lapatinib is a small molecule that can cross the blood-brain barrier for cancers that have spread there. (onclive.com)
  • About 10% to 20% are squamous cell carcinomas (cancer that forms in the thin, flat cells lining the inside of the lungs). (cdc.gov)
  • Adenocarcinomas and squamous cell carcinomas are two types of non-small cell lung cancer. (cdc.gov)
  • A cavitating right lower lobe squamous cell carcinoma. (medscape.com)
  • KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. (merck.com)
  • Cancer Lett, 300:215-224.doi:10.1016/j. squamous cell carcinoma in north-eastern Iran. (who.int)
  • Squamous cell carcinoma (SCC) is by far the most common of HIV-positivity in men with SCC of the penis treated at type of penile cancer.1 The mean age of men with SCC of the our institution, and to determine its relationship to age at penis varies from 55 to 63 years in studies from Europe and presentation and HPV infection. (who.int)
  • Conclusion: By the positive expression of p63 and TTF-1, the cases were labelled as squamous cell carcinoma and primary adenocarcinoma of lung, with due considerations given to the clinical and radiological parameters. (who.int)
  • Here, we aim to study if X-ray irradiation can induce de-methylation of the Dab2 gene and subsequently up-regulate its expression, and also to attempt to suppress the malignant biological behavior of and enhance the radiosensitivity in lung cancer cells with hypermethylation of the Dab2 gene. (duke.edu)
  • Colony Formation, matrigel invasion and xenograft experiment were performed to evaluate the malignant biological behavior of lung cancer cells with irradiation. (duke.edu)
  • Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. (cun.es)
  • A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA). (bvsalud.org)
  • Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. (empr.com)
  • E6 and Metabolic syndrome and risks of colon and rectal renal cell carcinoma. (who.int)
  • What Types of Lung Cancer Are Diagnosed in People Who Never Smoked? (cdc.gov)
  • Stage 1A: The cancer affects the lung only, with a tumor that measures 3 cm or smaller and hasn't spread to lymph nodes or other areas. (cancercenter.com)
  • In some cases, the lung tumor is larger than 3 cm, but smaller than 4 cm, and hasn't metastasized to lymph nodes. (cancercenter.com)
  • In some cases, the lung cancer tumor measures 5 cm or smaller and has reached lymph nodes located in the same area of the chest as the original tumor-typically lymph nodes in the lung or close to the bronchus. (cancercenter.com)
  • The tumor is smaller than 7 cm, but larger than 5 cm. (cancercenter.com)
  • At least one additional tumor has formed in the same part of the lung where the original tumor was detected. (cancercenter.com)
  • IL8 levels were monitored by sandwich ELISAs in cultured tumor cells supernatants, tumor-xenografted mice serum, and in samples from 126 patients with cancer. (cun.es)
  • IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. (cun.es)
  • The TNM (tumor-node-metastasis) staging system from the American Joint Committee for Cancer Staging and End Results Reporting is used for all lung carcinomas except small-cell lung cancer. (medscape.com)
  • Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. (genome.jp)
  • Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. (genome.jp)
  • RESULTS: The result of immunostaining of Dab2 in lung cancer tissues showed that decreased Dab2 expression was positively correlated with poor differentiation, lymph node metastasis, advanced TNM stage and poor prognosis. (duke.edu)
  • Closing out 2020, Bristol Myers Squibb announced their decision to withdraw the indication for nivolumab ( Opdivo ) for the treatment of patients with small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy and at least 1 other line of therapy. (clinicaladvisor.com)
  • Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases. (genome.jp)
  • If you do have lung cancer, your provider will do other tests to find out how far it has spread through the lungs, lymph nodes, and the rest of the body. (medlineplus.gov)
  • Other particles may be engulfed by epithelial cells, primarily in the vicinity of the bronchial-alveolar duct junctions, and retained for much longer periods, with gradual removal to lymph nodes. (cdc.gov)
  • The procedure of removing and examining tissue, cells, or fluids from the living body. (cdc.gov)
  • The cancer has reached the innermost tissue that wraps around the lung. (cancercenter.com)
  • Under a magnification of 250X, this unstained photomicrograph of a Lewis lung carcinoma (LLC) cell line tissue culture, depicted a small colony of pleuropneumonia-like organisms (PPLO), surrounded by a number of smaller like colonies, all exhibiting what was categorized as a morphologically typical growth pattern. (cdc.gov)
  • Dissecting the genetic alterations involved in lung carcinogenesis. (genome.jp)
  • However, sputum (mucus from the lungs) or bronchial washings (a sample of cells from inside the airways) may reveal the presence of cancer cells. (cancercenter.com)
  • Supplementary Data: STK1p as a prognostic biomarker for overall survival in non-small cell lung carcinoma, based on real-world-data. (figshare.com)
  • Human epidermal growth factor receptor 2, also known as HER2/neu (ERBB2), is a receptor tyrosine kinase that helps regulate cell survival and proliferation. (onclive.com)
  • Smoking cessation and survival in lung, upper aero-digestive tract and 73(1):166-72. (who.int)
  • In the most recent revision of the American Joint Committee on Cancer staging system for lung cancer,[1] T3N0 tumors were reassigned from stage IIIA to stage IIB, due to their distinctively more favorable prognosis, when compared with lymph-node-positive subgroups of stage IIIA disease. (cancernetwork.com)
  • Lung cancer is a disease that develops in lung tissues, especially in the lining of the airways. (cancercenter.com)
  • The mechanisms involved in the progression of disease process leading to fibrosis after avoidance of direct antigen contacts are under investigation implicating that indirect exposure to birds and/or the persistence of antigen in the lung may be responsible for ensuing pulmonary fibrosis. (nii.ac.jp)
  • See also Lung Cancer Staging -- Radiologic Options , a Critical Images slideshow, to help identify stages of the disease process. (medscape.com)
  • Primary spontaneous pneumothorax (PSP) is the presence of air in the pleural space, occurring in the absence of trauma and known lung disease. (bvsalud.org)
  • Primary achalasia is the most common subtype and is associated with loss of ganglion cells in the esophageal myenteric plexus. (medscape.com)
  • Patterns of genetic mutations can help determine cancer type (which can help when a clinician is faced with a classification of carcinoma of unknown primary origin). (medscape.com)
  • Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. (genome.jp)
  • HER2 bulges outside affected cancer cells rather than hiding inside, making it a good target for drugs. (onclive.com)
  • Another HER2-targeting drug is lapatinib (Tykerb), a dual tyrosine kinase inhibitor that disrupts different cell signaling pathways. (onclive.com)
  • It binds to mutated HER2 , where the receptor does not protrude properly from the cell. (onclive.com)
  • advanced non-small-cell lung cancer of the kind known as 'non-squamous', where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment. (europa.eu)
  • Approximately 80% of all patients with lung cancer are considered for systemic therapy at some point during the course of their illness. (medscape.com)
  • X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma cells. (duke.edu)
  • We previously reported that Dab2 was down-regulated due to gene promoter hypermethylation in lung cancer. (duke.edu)
  • X-ray treatment significantly inhibits proliferation and invasion of lung cancer cells with hypermethylation of the Dab2 gene promoter, but is less effective in lung cancer cells with hypomethylation of the Dab2 gene promoter. (duke.edu)
  • These results indicate that the methylation status of the Dab2 gene promoter might be a potential predictor of the radiosensitivity of lung cancer cells. (duke.edu)
  • People with lung cancer who have never smoked may have a DNA mutation, such as a mutation in the epidermal growth factor receptor (EGFR) gene or other genes. (cdc.gov)
  • The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. (genome.jp)
  • The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control. (genome.jp)
  • Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. (genome.jp)
  • The earlier in life you start smoking, the longer you smoke, and the more cigarettes you smoke per day, the greater your risk of lung cancer. (medlineplus.gov)
  • You can help lower your risk of lung cancer by staying away from secondhand smoke, diesel exhaust, and other air pollution, as well as asbestos, arsenic, and some forms of silica and chromium. (cdc.gov)
  • Tobacco smoking causes about 9 out of 10 cases of lung cancer in men and about 8 out of 10 cases of lung cancer in women. (medlineplus.gov)
  • Additional evidence supporting the net benefit of low-dose chest CT screening for lung cancer, and increased experience in mini. (bvsalud.org)
  • Hepatocellular Carcinomas from Iran: Evidence study of lung cancer among European asphalt carcinoma among postmenopausal women in the for Lack of Association between HBV Genotype workers. (who.int)
  • Patients' age, HIV status, histological type of carcinoma and evidence of HPV infection were recorded. (who.int)
  • For most patients with lung cancer, current treatments do not cure the cancer. (medlineplus.gov)
  • Unfortunately, this is not everybody and it's a smaller number of patients that go 5 years. (medscape.com)
  • In contrast, the insidious BFL patients were likely to be exposed to smaller sized birds kept indoors, clubbed fingers were observed in 53%, specific antibod … More ies against pigeon dropping extracts or budgerigar dropping extracts were positive in only 35% showing that the remaining 65% patients were negative. (nii.ac.jp)
  • Peripheral blood mononuclear cells from HP patients proliferated in the presence of the antigen and showed enhanced expression of mRNA of proinflammatory cytokines including IL-β and IL-6 as well as IL-2R. (nii.ac.jp)
  • Among the 25 lung cancer patients, 17 were smokers at the time of hospitalization or were former smokers. (cdc.gov)
  • 2015). Post-operative smoking status in lung and head and neckcan- of the duration of preoperative smoking cessation to improve wound cer patients: association with depressive symptomatology, pain, and healing after head and neck surgery. (who.int)
  • Effect of cigarette smoking on quality of life in small cell lung cancer exposure-safety relationship in patients with non-small cell lung can- patients. (who.int)
  • Patients with penile carcinoma had a high prevalence of HIV infection. (who.int)
  • Lung cancer is cancer that forms in tissues of the lung, usually in the cells that line the air passages. (medlineplus.gov)
  • When abnormal cells are detected in the tissues that line the respiratory tract. (cancercenter.com)
  • These cells may turn cancerous and affect other nearby tissues. (cancercenter.com)
  • That's because the possible harms of screening outweigh the possible benefit (finding lung cancer early) in this group. (cdc.gov)
  • Is Lung Cancer Screening Recommended for People Who Never Smoked? (cdc.gov)
  • The U.S. Preventive Services Task Force does not recommend lung cancer screening for people who have never smoked. (cdc.gov)
  • Low-dose chest CT screening for lung cancer has become a standard of care in the United States, in large part because of the results of the National Lung Screening Trial (NLST). (bvsalud.org)
  • Examples include exposure to other people's smoke (called secondhand smoke), radon, air pollution, a family history of lung cancer, and asbestos. (cdc.gov)
  • Immunotherapy in lung cancer is a little bit glass half-full or glass half-empty or, being a New Yorker by birth, maybe who drank my water? (medscape.com)
  • And I know we discussed that concept a bit with our immunotherapy conversation and in the setting of non-small cell lung cancer, and it's even more emphasized in small cell lung cancer. (medscape.com)
  • Either a portion of or the entire lung has collapsed or has pneumonitis (a condition in which the lung becomes inflamed). (cancercenter.com)
  • Either a portion of or the entire lung has collapsed or has pneumonitis. (cancercenter.com)
  • Fourteen years ago, the genomic community sequenced its first cancer exome [the protein-coding region], and it was able to identify mutations in roughly 20,000 protein-coding genes in the human cell. (medscape.com)
  • Dr Weiss is a professor of medicine at UNC's Lineberger Comprehensive Cancer Center, where he runs a joint lung and head and neck cancer section. (medscape.com)
  • Systematic review of tobacco use after lung or head/neck cancer diagnosis: results and sessment of tobacco use in clinical cancer research. (who.int)
  • When you inhale it, you are exposed to the same cancer-causing agents as smokers, although in smaller amounts. (medlineplus.gov)
  • He is director of the Bioinformatics and Integrative Genomics (BIG) Ph.D. program at Harvard Medical School and a member of the Informatics Program at Boston Children's Hospital, Division of Genetics at Brigham and Women's Hospital, Harvard/Dana-Farber Cancer Center, and the Harvard Stem Cell Institute. (harvard.edu)
  • This retrospective study investigated all men with penile carcinoma at the Universitas Academic Hospital in Bloemfontein, South Africa (January 2000-December 2008). (who.int)
  • What are the symptoms of lung cancer? (medlineplus.gov)
  • Sometimes lung cancer does not cause any signs or symptoms. (medlineplus.gov)
  • You may not have symptoms," says Jackie, a lung cancer survivor who never smoked. (cdc.gov)
  • What Are the Symptoms of Lung Cancer Among People Who Never Smoked? (cdc.gov)
  • Symptoms of lung cancer are the same, whether or not you have smoked. (cdc.gov)
  • Bisulfite sequencing PCR (BSP) was used to evaluate the methylation status of lung cancer cells with or without X-ray treatment. (duke.edu)
  • Knowing the type and stage of lung cancer you have helps your provider decide what kind of treatment you need. (medlineplus.gov)
  • Your treatment will depend on which type of lung cancer you have, how far it has spread, your overall health, and other factors. (medlineplus.gov)
  • Are We Ready to Use the Word 'Cure' When Talking About Small Cell Lung Cancer Treatment? (medscape.com)
  • Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. (merck.com)
  • Impact of smoking on lung cancer treatment effectiveness: a review. (who.int)
  • The absence of signal in the STAT1 knock-out A549 cells confirms specificity of the antibody for STAT1. (cellsignal.com)
  • The type of carcinoma and the presence or absence of HPV infection were confirmed by one pathologist (JG) who reviewed the histology slides. (who.int)
  • The conversion of pemetrexed into its active form occurs more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells. (europa.eu)
  • This results in the division of cancer cells being reduced, while normal cells are only slightly affected. (europa.eu)